<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7140032</article-id><article-id pub-id-type="doi">10.3390/cancers12030743</article-id><article-id pub-id-type="publisher-id">cancers-12-00743</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Gauging the Impact of Cancer Treatment Modalities on Circulating Tumor Cells (CTCs)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2830-8475</contrib-id><name><surname>Mathias</surname><given-names>Trevor J.</given-names></name><xref ref-type="aff" rid="af1-cancers-12-00743">1</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Katarina T.</given-names></name><xref ref-type="aff" rid="af1-cancers-12-00743">1</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Stuart S.</given-names></name><xref ref-type="aff" rid="af2-cancers-12-00743">2</xref><xref ref-type="aff" rid="af3-cancers-12-00743">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8055-9645</contrib-id><name><surname>Vitolo</surname><given-names>Michele I.</given-names></name><xref ref-type="aff" rid="af2-cancers-12-00743">2</xref><xref ref-type="aff" rid="af3-cancers-12-00743">3</xref><xref rid="c1-cancers-12-00743" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cancers-12-00743"><label>1</label>Program in Molecular Medicine, University of Maryland Graduate Program in Life Sciences, Baltimore, MD 21201, USA; <email>Trevor.Mathias@som.umaryland.edu</email> (T.J.M.); <email>ktchang@som.umaryland.edu</email> (K.T.C.)</aff><aff id="af2-cancers-12-00743"><label>2</label>Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; <email>ssmartin@som.umaryland.edu</email></aff><aff id="af3-cancers-12-00743"><label>3</label>Stewart Greenebaum NCI Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA</aff><author-notes><corresp id="c1-cancers-12-00743"><label>*</label>Correspondence: <email>mvitolo@som.umaryland.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2020</year></pub-date><volume>12</volume><issue>3</issue><elocation-id>743</elocation-id><history><date date-type="received"><day>01</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>19</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The metastatic cascade consists of multiple complex steps, but the belief that it is a linear process is diminishing. In order to metastasize, cells must enter the blood vessels or body cavities (depending on the cancer type) via active or passive mechanisms. Once in the bloodstream and/or lymphatics, these cancer cells are now termed circulating tumor cells (CTCs). CTC numbers as well as CTC clusters have been used as a prognostic marker with higher numbers of CTCs and/or CTC clusters correlating with an unfavorable prognosis. However, we have very limited knowledge about CTC biology, including which of these cells are ultimately responsible for overt metastatic growth, but due to the fact that higher numbers of CTCs correlate with a worse prognosis; it would seem appropriate to either limit CTCs and/or their dissemination. Here, we will discuss the different cancer treatments which may inadvertently promote the mobilization of CTCs and potential CTC therapies to decrease metastasis.</p></abstract><kwd-group><kwd>cancer</kwd><kwd>metastasis</kwd><kwd>circulating tumor cells</kwd><kwd>CTCs</kwd><kwd>dissemination</kwd><kwd>chemotherapy</kwd><kwd>radiotherapy</kwd><kwd>surgery resection</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-12-00743"><title>1. Introduction</title><p>For a majority of cancers, the 5-year survival rate of patients who present with localized or regional disease is steadily trending upwards [<xref rid="B1-cancers-12-00743" ref-type="bibr">1</xref>] (US National Cancer Institute Surveillance, Epidemiology, and End Result (SEER) registries&#x02014;data from 1995&#x02013;2000 and 2004&#x02013;2020 collected in 2005 and 2015 respectively). However, upon development of metastatic disease, not only do survival percentages plummet, but there has not been any increase, and in many cancer subtypes a decrease, in the 5-year survival rates for most metastatic cancers (breast, bladder, melanoma, ovarian, pancreatic, prostate, cervical, uterine). The few exceptions are colorectal, esophageal, lung, and oral cancer metastases, where there is only a very minimal increase in 5-year survival (mostly less than 3%) [<xref rid="B1-cancers-12-00743" ref-type="bibr">1</xref>] (US SEER registries&#x02014;data from 1995&#x02013;2000 and 2004&#x02013;2020 collected in 2005 and 2015 respectively). This is likely due to the focus of both drug development and clinical efficacy studies on inhibition and regression of tumor cell growth which largely ignores circulating or disseminated tumor cells, which could be an important, yet an under-examined phase of the metastatic cascade. In light of recent studies showing that radiotherapy, surgery and chemotherapy have the potential to dramatically increase levels of tumor cells in the bloodstream even if the primary tumor is successfully removed or destroyed [<xref rid="B2-cancers-12-00743" ref-type="bibr">2</xref>,<xref rid="B3-cancers-12-00743" ref-type="bibr">3</xref>], understanding the complex biology of CTC dissemination is paramount. </p></sec><sec id="sec2-cancers-12-00743"><title>2. CTCs and Metastatic Efficiency</title><p>By the time a primary cancer mass is clinically detectable, it contains a minimum of 10<sup>7</sup>&#x02013;10<sup>8</sup> cells (approximately the size of 0.5 cm<sup>3</sup>) [<xref rid="B4-cancers-12-00743" ref-type="bibr">4</xref>,<xref rid="B5-cancers-12-00743" ref-type="bibr">5</xref>]. Tumors may only reach this size and continue their growth by promoting new and incorporating current vasculature via angiogenesis [<xref rid="B6-cancers-12-00743" ref-type="bibr">6</xref>]. The resulting vessels provide nutrients for the growing tumor as well as access for mobilized tumor cells. Even a small primary tumor with neovasculature can &#x0201c;shed&#x0201d; millions of tumor cells daily into the bloodstream by the time of first detection. Over 40 years ago, Butler and Gullino determined that 1.7&#x02013;4.6 &#x000d7; 10<sup>6</sup> tumor cells were shed every 24 hour per gram from growing hormone dependent rat mammary tumors [<xref rid="B7-cancers-12-00743" ref-type="bibr">7</xref>]. However, although tumors may release millions of CTCs daily, a vast majority die due to the inhospitable environment within the vasculature. Thus, hematological metastasis is a highly inefficient process (<xref ref-type="fig" rid="cancers-12-00743-f001">Figure 1</xref>). Any hematologic disseminated CTCs (at this point, more correctly termed disseminated tumor cells or DTCs) need to be able to survive hemodynamic stress and trapping within capillaries, need to adhere to the endothelial cell wall and extravasate into the surrounding tissue with a potential suitable metastatic niche where they may remain dormant. The potential result of hematologic dissemination is distant metastases, opposed to local metastasis to the lymph nodes which likely occurs through the lymphatics. DTCs may be able to initiate growth to form a micrometastases, but then these microscopic secondary tumors need to recruit new and existing vasculature once again in order to continue grow into a clinically relevant macrometastases [<xref rid="B8-cancers-12-00743" ref-type="bibr">8</xref>]. The percent efficiency of CTCs able to metastasize is likely dependent on cancer type, mutations, immune system evasion, and metastatic niche requirements. An early study aimed to determine metastatic efficiency of CTCs was performed by Fidler [<xref rid="B9-cancers-12-00743" ref-type="bibr">9</xref>]. Labeled B16 melanoma cells were injected (2 &#x000d7; 10<sup>5</sup>) into the tail vein of mice and after 14 days, an average of only 400 cells remained in the lungs. Additionally, an average of 78 pleural metastases (&#x0003c;0.04%) and a lesser unknown number of interior parenchymal metastases occur presumably in mice allowed to live past 14 days. Unfortunately, it is unknown whether these are clinically relevant micrometastases, especially since the majority of micrometastases are not likely to progress to overt metastases. Luzzi et al. [<xref rid="B10-cancers-12-00743" ref-type="bibr">10</xref>] used a similar model of metastasis, injecting fluorescently labeled B16 melanoma cells into the superior mesenteric vein and determined that 2% of the injected cells formed micrometastases in the liver, only 1 out of 100 of these micrometastases would go on to form a macroscopic tumor (~0.02% of injected cells). Both studies employed highly metastatic B16 melanoma cells. It is likely that the metastatic efficiency is lower for other cancers. Supporting this notion is a modelling study completed using a large cohort of patients with breast cancer which determined that only 1 CTC from every 60 million cells escaping from the primary tumor has the ability to metastasize [<xref rid="B11-cancers-12-00743" ref-type="bibr">11</xref>] which equated to less than 0.000002%. The good news is that the metastatic process is highly inefficient, but the not so good news is that tumors may be shedding large numbers of CTCs very early during their development. It is very possible that at the time of regional or even local diagnosis, tumors cells have already disseminated, and may be existing below the levels of clinical detection as either single cell or micrometastases. Other studies which analyzed expression profiles from matched primary and metastatic samples support a nonlinear process for metastasis. A &#x0201c;poor prognosis&#x0201d; genomic signature was similarly found in both primary and matched metastases [<xref rid="B12-cancers-12-00743" ref-type="bibr">12</xref>,<xref rid="B13-cancers-12-00743" ref-type="bibr">13</xref>,<xref rid="B14-cancers-12-00743" ref-type="bibr">14</xref>]. The findings suggest that cells released early from a small primary tumor may already have the potential to form metastases [<xref rid="B15-cancers-12-00743" ref-type="bibr">15</xref>]. Another study using mouse models of breast cancer, initially reasoned that if the metastatic process is linear, even if dissemination of tumor cells occurs early, it is only the genetically-progressed cancer cells that would have metastatic capabilities [<xref rid="B16-cancers-12-00743" ref-type="bibr">16</xref>]. However, comparative genomic hybridization (CGH) profiling from DTCs harvested from the mouse bone marrow were indistinguishable from early harvests (9 weeks) and late harvests (27 weeks). Surprisingly, there was no detectable increase in genomic aberrations from the younger to older animals. This study appears to suggest that metastatic dissemination is not a result of selection of the tumor cells within the tumor. Data from another comparative genomic analysis using a parallel progression model of primary and metastatic cells identified DTCs in the bone marrow of 607 breast cancer patients regardless of stage or primary tumor size [<xref rid="B16-cancers-12-00743" ref-type="bibr">16</xref>], these findings support a model where the metastatic process seems to begin almost simultaneously with tumorigenesis. </p></sec><sec id="sec3-cancers-12-00743"><title>3. Mechanisms for Tumor Cells to Enter the Vasculature</title><p>One reason for the low metastatic efficiency of cancer cells, is that the majority of CTCs are likely pre- or post-apoptotic upon entering the bloodstream [<xref rid="B17-cancers-12-00743" ref-type="bibr">17</xref>,<xref rid="B18-cancers-12-00743" ref-type="bibr">18</xref>]. Different areas of tumors are likely actively growing and dying simultaneously. Due to poor perfusion and insufficient delivery of oxygen and nutrients, tumors may have a necrotic core and/or necrotic pockets within the full tumor. The recruited vasculature is immature and disorganized with an abnormal or absent basement membrane promoting &#x0201c;leakiness&#x0201d; of the vessels (reviewed in [<xref rid="B19-cancers-12-00743" ref-type="bibr">19</xref>]). The tumor vasculature is inadequate to maintain consistently viable tumor cells, and it also acts as a conduit for dying or dead tumor cells to passively enter the bloodstream. Even before the cells enter the inhospitable environment of the bloodstream, the majority is, or will soon be, dead. Of specific importance are the viable cells which enter the vasculature. Basic enumeration studies do not currently distinguish the viable CTCs from those which are not viable, however there are some limited studies that examine CTC viability [<xref rid="B20-cancers-12-00743" ref-type="bibr">20</xref>,<xref rid="B21-cancers-12-00743" ref-type="bibr">21</xref>,<xref rid="B22-cancers-12-00743" ref-type="bibr">22</xref>]. High levels of viable CTCs would predict a poorer prognosis than that from dead CTCs. These cells may passively or actively enter the bloodstream. It is possible that dissociating tumor cells at the leading edge of the tumor are &#x0201c;pushed&#x0201d; into the bloodstream by the division and expansion of the cells behind them [<xref rid="B23-cancers-12-00743" ref-type="bibr">23</xref>]. Intravasating tumor cells may also find the abnormal vasculature an easy entryway into the bloodstream. However, cancer cells are also capable of &#x0201c;squeezing&#x0201d; through an endothelial cell layer, then degrading the extracellular matrix and the basement membrane underlying the endothelial cells. Interestingly, in vitro studies examining this active intravasation process show insignificant interruption of the endothelial cell barrier [<xref rid="B24-cancers-12-00743" ref-type="bibr">24</xref>]. Detailed mechanisms for how the tumor cells migrate through or between the tight junctions of the endothelial cells remains unknown. In many cases, in order for tumor cells to migrate and invade, they undergo an Epithelial to Mesenchymal Transition (EMT) [<xref rid="B25-cancers-12-00743" ref-type="bibr">25</xref>,<xref rid="B26-cancers-12-00743" ref-type="bibr">26</xref>,<xref rid="B27-cancers-12-00743" ref-type="bibr">27</xref>,<xref rid="B28-cancers-12-00743" ref-type="bibr">28</xref>]. EMT is a developmental program normally employed during embryogenesis and during the healing of epithelial tissues in adults. Carcinoma cells can inappropriately utilize this process to gain certain mesenchymal features while losing some epithelial traits, promoting increased malignant traits such as increased migration and invasion. In line with the idea that metastatic progression is not linear, some studies have shown that cells can acquire EMT traits to disseminate early, even when lesions are preneoplastic [<xref rid="B16-cancers-12-00743" ref-type="bibr">16</xref>,<xref rid="B29-cancers-12-00743" ref-type="bibr">29</xref>]. While a large body of evidence supports carcinoma cells undergoing EMT programs in breast, colorectal, ovarian, pancreatic, prostate, renal and other cancers [<xref rid="B30-cancers-12-00743" ref-type="bibr">30</xref>,<xref rid="B31-cancers-12-00743" ref-type="bibr">31</xref>,<xref rid="B32-cancers-12-00743" ref-type="bibr">32</xref>,<xref rid="B33-cancers-12-00743" ref-type="bibr">33</xref>,<xref rid="B34-cancers-12-00743" ref-type="bibr">34</xref>,<xref rid="B35-cancers-12-00743" ref-type="bibr">35</xref>,<xref rid="B36-cancers-12-00743" ref-type="bibr">36</xref>,<xref rid="B37-cancers-12-00743" ref-type="bibr">37</xref>], the cells do not make a complete switch from all epithelial to all mesenchymal characteristics. Even more studies have begun to highlight the likelihood of a partial EMT in which tumor cells retain the appropriate levels of epithelial qualities while acquiring some mesenchymal properties for optimal metastatic potential [<xref rid="B26-cancers-12-00743" ref-type="bibr">26</xref>,<xref rid="B38-cancers-12-00743" ref-type="bibr">38</xref>,<xref rid="B39-cancers-12-00743" ref-type="bibr">39</xref>,<xref rid="B40-cancers-12-00743" ref-type="bibr">40</xref>,<xref rid="B41-cancers-12-00743" ref-type="bibr">41</xref>,<xref rid="B42-cancers-12-00743" ref-type="bibr">42</xref>,<xref rid="B43-cancers-12-00743" ref-type="bibr">43</xref>,<xref rid="B44-cancers-12-00743" ref-type="bibr">44</xref>,<xref rid="B45-cancers-12-00743" ref-type="bibr">45</xref>,<xref rid="B46-cancers-12-00743" ref-type="bibr">46</xref>,<xref rid="B47-cancers-12-00743" ref-type="bibr">47</xref>]. </p><p>A shift toward a more mesenchymal phenotype will affect CTC collection efficiency. Currently, the only FDA approved method for CTC collection is the CellSearch system which utilizes epithelial cell markers for identification, but tumor cells may downregulate or lose these markers before or during dissemination [<xref rid="B22-cancers-12-00743" ref-type="bibr">22</xref>]. Other methods of CTC isolation are label-free techniques utilizing filtration and fluid dynamics based on tumor cells size and deformability and not on epithelial marker detection. Different CTC collection and isolation techniques have been extensively reviewed, and thus will not be discussed here (reviewed in [<xref rid="B48-cancers-12-00743" ref-type="bibr">48</xref>,<xref rid="B49-cancers-12-00743" ref-type="bibr">49</xref>,<xref rid="B50-cancers-12-00743" ref-type="bibr">50</xref>,<xref rid="B51-cancers-12-00743" ref-type="bibr">51</xref>,<xref rid="B52-cancers-12-00743" ref-type="bibr">52</xref>,<xref rid="B53-cancers-12-00743" ref-type="bibr">53</xref>,<xref rid="B54-cancers-12-00743" ref-type="bibr">54</xref>]). However, it is important to recognize that all studies discussed in this review did not use the same CTC isolation method and any incompatible results may be attributed to different CTC isolation approaches, and a component of variability is likely due to differences in detection method.</p><p>Some tumor cells may have the ability to migrate collectively. In such cases, the tumors retain E-cadherin expression indicative of an epithelial phenotype which allows for the cells to remain attached via cell-cell junction [<xref rid="B55-cancers-12-00743" ref-type="bibr">55</xref>,<xref rid="B56-cancers-12-00743" ref-type="bibr">56</xref>]. Tumor cells may also invade into the vasculature with macrophages as partners [<xref rid="B57-cancers-12-00743" ref-type="bibr">57</xref>,<xref rid="B58-cancers-12-00743" ref-type="bibr">58</xref>,<xref rid="B59-cancers-12-00743" ref-type="bibr">59</xref>]. Macrophages and tumor cells alternate in single file, and it is suggested that the macrophages secrete proteinases to promote the tumor cells, deficient in overactive proteinase production, to invade. Even if CTCs intravasate as single cells, some can activate and cause aggregation of platelets leading to the formation of tumor cell-induced platelet aggregations. These aggregations enhance CTC survival by protecting them from immune attacks and enhance small vessel trapping [<xref rid="B60-cancers-12-00743" ref-type="bibr">60</xref>]. Tumor-derived microemboli may also be released into the bloodstream [<xref rid="B61-cancers-12-00743" ref-type="bibr">61</xref>,<xref rid="B62-cancers-12-00743" ref-type="bibr">62</xref>,<xref rid="B63-cancers-12-00743" ref-type="bibr">63</xref>], and CTC clusters, ranging from 2&#x02013;50 cells, have been detected in the circulation of metastatic cancer patients [<xref rid="B61-cancers-12-00743" ref-type="bibr">61</xref>,<xref rid="B63-cancers-12-00743" ref-type="bibr">63</xref>,<xref rid="B64-cancers-12-00743" ref-type="bibr">64</xref>,<xref rid="B65-cancers-12-00743" ref-type="bibr">65</xref>,<xref rid="B66-cancers-12-00743" ref-type="bibr">66</xref>]. Although CTC clusters are rare, they have a 23- to 50-fold increase in metastatic potential [<xref rid="B67-cancers-12-00743" ref-type="bibr">67</xref>] for a multitude of reasons. Clumps of cells have more protection from sheer stress, may be better hidden from immune surveillance, and larger emboli can more efficiently trap in smaller vessels as the diameter decreases [<xref rid="B9-cancers-12-00743" ref-type="bibr">9</xref>,<xref rid="B61-cancers-12-00743" ref-type="bibr">61</xref>,<xref rid="B68-cancers-12-00743" ref-type="bibr">68</xref>].</p><p>Metastasis requires the dissemination of primary tumor cells, and passage via the bloodstream (i.e., hematogeneous) allows for an extensive dissemination. However, it should be noted that some metastases may not arise from CTCs since some tumor cells have been shown to migrate along nerves [<xref rid="B69-cancers-12-00743" ref-type="bibr">69</xref>,<xref rid="B70-cancers-12-00743" ref-type="bibr">70</xref>,<xref rid="B71-cancers-12-00743" ref-type="bibr">71</xref>] or along endothelial cells [<xref rid="B72-cancers-12-00743" ref-type="bibr">72</xref>].</p></sec><sec id="sec4-cancers-12-00743"><title>4. Current Anti-Tumor Therapies may Inadvertently Increase CTCs</title><p>Surgery, radiotherapy, and/or chemotherapy are current standards of care for locoregional disease. Unfortunately, some patients develop distant metastases either prior to diagnosis or despite initial treatment of local disease. One reasonable explanation is that the metastases are already present at the time of initial diagnosis and therapy, but below our thresholds of detection, and over time, eventually grow to macroscopic masses. However, accumulating evidence suggests the treatments to control locoregional disease may, in some cases, promote metastasis [<xref rid="B48-cancers-12-00743" ref-type="bibr">48</xref>,<xref rid="B73-cancers-12-00743" ref-type="bibr">73</xref>] (<xref ref-type="fig" rid="cancers-12-00743-f002">Figure 2</xref>). CTC collection and enumeration studies have shown CTC numbers correlate with disease progression and metastasis in different human cancers where increasing numbers are predictive of lower PFS and OS [<xref rid="B74-cancers-12-00743" ref-type="bibr">74</xref>,<xref rid="B75-cancers-12-00743" ref-type="bibr">75</xref>,<xref rid="B76-cancers-12-00743" ref-type="bibr">76</xref>,<xref rid="B77-cancers-12-00743" ref-type="bibr">77</xref>,<xref rid="B78-cancers-12-00743" ref-type="bibr">78</xref>,<xref rid="B79-cancers-12-00743" ref-type="bibr">79</xref>,<xref rid="B80-cancers-12-00743" ref-type="bibr">80</xref>,<xref rid="B81-cancers-12-00743" ref-type="bibr">81</xref>,<xref rid="B82-cancers-12-00743" ref-type="bibr">82</xref>,<xref rid="B83-cancers-12-00743" ref-type="bibr">83</xref>,<xref rid="B84-cancers-12-00743" ref-type="bibr">84</xref>], but it is unknown whether current treatments are directly influencing CTCs or whether CTCs released during therapy are capable of forming overt metastases. Preliminary studies have shown all cancer treatment modalities have a potential to increase CTCs. These studies are preliminary, and in some cases, use small sample sizes and therefore statistical significance remains to be determined. Below is a summary of preclinical and clinical data in which treatments necessary for cancer control may increase CTCs in some patients. </p><sec id="sec4dot1-cancers-12-00743" sec-type="methods"><title>4.1. Surgical Procedures</title><p>In order to determine whether surgery directly affects the dissemination of tumor cells within the vasculature, a baseline of CTCs would need to be established relatively close but prior to surgery and blood containing CTCs would need to be collected at the time of surgery. Collection of CTCs at a single time point 24 h post-surgery (likely even an hour after surgery) will not accurately determine the effect of mechanical manipulation of surgery due to CTC clearance. The process of CTC clearance can be from successful dissemination or, more commonly, due to death. On the other hand, waiting too long (likely longer than a few days) may also yield inaccurate results. Measuring CTCs at longer time points post-surgery may be complicated by new CTCs released from metastatic or unresected sites induced to proliferate upon primary tumor removal [<xref rid="B86-cancers-12-00743" ref-type="bibr">86</xref>]. Instead, there have only been a few published studies on perioperative detection of CTCs or following tumor/ organ removal, and most of these have involved low patient numbers summarized below.</p><p>An early study from Hansen et al. [<xref rid="B87-cancers-12-00743" ref-type="bibr">87</xref>] detected tumors cells in blood collected intraoperatively in 57 of 61 patients with cancer who underwent surgery for an abdominal, orthopedic, urological, gynecological, or head and neck malignant tumors. Unfortunately, the study did not include collecting blood prior to surgery to determine whether CTCs increased as a direct result of oncologic surgery, so alterations to CTCs could not be assessed. More recent studies have been performed to specifically answer whether surgical procedures promote increases in CTCs. For example, blood samples were collected from before and during lung cancer surgery, and CTCs were quantified and compared in both conditions [<xref rid="B88-cancers-12-00743" ref-type="bibr">88</xref>]. The blood collected in this study was from the pulmonary vein of 30 patients undergoing lobectomies and open thoracotomies. Before surgical manipulation, CTCs were detected in a majority of patients and at the time of completion of the lobectomy, CTC counts significantly increased. A separate study examining 20 patients with colorectal cancer with already established liver metastases reported that 50% of cases had an increase in CTCs during hepatic lesion resection [<xref rid="B89-cancers-12-00743" ref-type="bibr">89</xref>]. One study examining CTCs in patients with non-small cell lung cancer (NSCLC), collected blood from each patient via the radial artery while the patients were under anesthesia. Blood was collected just before, during, and just after pulmonary vein dissection. Four of 16 patients originally negative for CTCs before surgery were positive following pulmonary vein dissection. The authors conclude that tumor cells can be dislodged and detected after lung cancer surgery [<xref rid="B90-cancers-12-00743" ref-type="bibr">90</xref>]. A larger study including 139 patients with hepatocellular carcinoma compared pre- and post-operative CTC numbers [<xref rid="B91-cancers-12-00743" ref-type="bibr">91</xref>]. Blood was harvested 1 day prior to surgery and immediately after surgery. Compared with the preoperative CTC counts, the postoperative CTC counts increased in 58 (41.7%) patients. It was concluded that surgical liver resection is associated with an increase in CTC counts. It should be noted that post-surgery, 35 (25.2%) patients had a decrease in CTCs and the CTC number did not change in 46 (33.1%) patients. Yet another recent study collected blood samples from the peripheral artery just before and immediately after partial or radical nephrectomy [<xref rid="B92-cancers-12-00743" ref-type="bibr">92</xref>] and compared CTC numbers between a laparoscopic or open surgical approach. Patients underwent laparoscopic partial or radical nephrectomy or open partial or radical nephrectomy. Open radical nephrectomy resulted in a significant increased number of CTC immediately post-surgery with no significant differences observed between the other three procedures. Additionally, a higher detection rate of CTC has been demonstrated in the blood of patients with liver, cervical, colorectal cancers following surgical procedures [<xref rid="B91-cancers-12-00743" ref-type="bibr">91</xref>,<xref rid="B93-cancers-12-00743" ref-type="bibr">93</xref>,<xref rid="B94-cancers-12-00743" ref-type="bibr">94</xref>]. Interestingly, there has yet to be a study implicating any surgical procedures relevant in breast cancer removal. As part of a study from Li et al. [<xref rid="B95-cancers-12-00743" ref-type="bibr">95</xref>], endoscopic and/or open radical mastectomy performed on 110 female patients with breast cancer showed a trend in increasing tumor cells from pre-surgical CTCs to post-surgical CTCs, but it did not reach significance. One limitation of this breast cancer study was the post-surgical blood draw occurring 12 h after surgery, allowing ample time CTC clearance.</p><p>Besides surgery, other lesser procedures have the ability to disrupt tumors and increase CTCs. Simple pressure which occurs during palpation can increase CTCs immediately. Using an in vivo photoacoustic and fluorescent flow cytometry technique to monitor CTC release in real time from mice transplanted with melanoma cells, a weight was used to approximate the pressure of palpation and applied to melanoma tumors on the backs of mice [<xref rid="B96-cancers-12-00743" ref-type="bibr">96</xref>]. CTCs increased during the time of the applied pressure and remained high for an hour after the pressure ended, after which, CTC number began to decline. Similar results were observed by squeezing the tumors with fingers, and CTCs were not detected using weights lower than 50g. Juratli et al. [<xref rid="B97-cancers-12-00743" ref-type="bibr">97</xref>] tried to replicate the results using breast cancer cells (MDA-MB-231) inoculated into a mammary gland. When the tumors approximated 50mm<sup>3</sup> (2 weeks), a weight (400g/0.5cm<sup>2</sup>) was placed atop to mimic the pressure from a mammogram. While there was a minor increase in CTCs detected while the tumor was under pressure, it did not reach significance. The same group also monitored CTC release after incisional biopsy, punch biopsy, and complete resection in their mouse models. During a 15-minute incisional biopsies of melanoma tumors, CTCs drastically increased and remained high for the first hour afterwards. After the first hour, the CTC rate lowered but was still significantly elevated above the rate from before biopsy and remained elevated until the end of the experiment (&#x0003e;2 h) [<xref rid="B96-cancers-12-00743" ref-type="bibr">96</xref>]. Punch biopsies of the mammary tumors increase CTCs which remained high for 2 h after the biopsy [<xref rid="B97-cancers-12-00743" ref-type="bibr">97</xref>]. Interestingly, no CTCs were observed during resection of the melanoma or mammary tumors or 2 hours post-surgery. Clinically, incisional biopsy has been shown to increase CTCs in 4 of 25 patients [<xref rid="B98-cancers-12-00743" ref-type="bibr">98</xref>] and 2 of 10 patients [<xref rid="B99-cancers-12-00743" ref-type="bibr">99</xref>] with oral squamous cell carcinoma. </p><p>Finally, fine or core needle biopsies are critical to diagnosing multiple cancers. Multiple studies have shown tumor cells have the ability to seed along the needle track [<xref rid="B100-cancers-12-00743" ref-type="bibr">100</xref>], but do these types of biopsies also promote CTCs? Mathenge et al. [<xref rid="B101-cancers-12-00743" ref-type="bibr">101</xref>] begin to answer this question using a mouse model of breast cancer and harvesting blood after needle biopsy. Six hours after needle biopsy, a significant increase in CTCs are detected. After needle biopsy, mammary tumors were removed from the mice which had their tumors biopsied and controls which did not. One week after tumor removal, all mice were sacrificed, and lungs were analyzed for metastasis. Mice which underwent biopsies harbored significantly greater lung metastases suggesting that the biopsies may unintentionally promote metastasis by causing CTC shedding. Of note, this study employed the highly aggressive metastatic murine breast cancer line, 4T1. These cells are primed for both metastatic dissemination and growth, and likely have multiple mechanisms to endure the stress of circulation, reattach, disseminate, and regrow in distant tissues. This does not mean all additional CTCs produced by biopsy will metastasize since metastasis is a very inefficient process. Furthermore, it has yet to be determined if any CTCs released by surgery or other mechanical manipulations are even viable. However, another study examines the use of transrectal ultrasound-guided biopsy (TRUS), a standard procedure used for prostate cancer diagnosis [<xref rid="B102-cancers-12-00743" ref-type="bibr">102</xref>]. Importantly, blood collection for CTC analysis was completed before and 30 min after prostate biopsy in 115 men with elevated PSA levels. Multiple (8&#x02013;12) tissue core biopsies are required for the detection of prostate cancer, as it is a multifocal disease, and these biopsies were associated with a significant increase in bloodborne prostate tumor cells in men with histologically confirmed cancer. No biopsy-related change was detected in the men without cancer, demonstrating that the normal gland will not shed cells during TRUS biopsy. The patients for whom increased CTC counts were observed, had a shorter progression-free survival, implying faster disease progression, independently from Gleason score, biopsy core positivity, and presence of CTCs at baseline. Since patients did not have clinically evident metastasis at primary diagnosis, it is unlikely the CTCs detected in this study arose from an alternative source besides the primary lesion. It is thus concluded that the mechanical trauma from TRUS led to the increase in CTCs, which ultimately affected disease propagation [<xref rid="B102-cancers-12-00743" ref-type="bibr">102</xref>].</p></sec><sec id="sec4dot2-cancers-12-00743"><title>4.2. Radiotherapy </title><p>Early experiments using animal models have indicated that multiple tumor types irradiated with low, non-curative doses of radiation, insufficient for local control, are associated with higher risk of metastasis [<xref rid="B103-cancers-12-00743" ref-type="bibr">103</xref>,<xref rid="B104-cancers-12-00743" ref-type="bibr">104</xref>,<xref rid="B105-cancers-12-00743" ref-type="bibr">105</xref>]. Interestingly, all metastases were localized to the lungs and in the Kaplan et al. [<xref rid="B104-cancers-12-00743" ref-type="bibr">104</xref>] study, the pulmonary metastases grew in the arteries and arterioles, implicating possible vascular transit from the primary tumor site. Another mouse model using Lewis Lung carcinoma cells grown in the hindlimbs of mice utilized radiation of the implanted tumors to accomplish local disease control. However, the irradiated mice had an increased rate of lung metastases compared to the non-irradiated mice [<xref rid="B106-cancers-12-00743" ref-type="bibr">106</xref>]. A more recent study showed an increase in CTCs from tumors of subcutaneously implanted 4T1 cells in the left rear limb at the first 10 and 20 min after a 12 Gy dose [<xref rid="B107-cancers-12-00743" ref-type="bibr">107</xref>] Although CTCs originally increased, there was no differences in CTC numbers between the irradiated mice and the control mice at 8 hours, and irradiation did not correlate with an increase in metastases. The authors reasoned that the lack of metastatic tumor burden following release of CTCs after high dose radiation therapy indicates low CTC viability, clonogenicity, or both. </p><p>Studies indicate that radiotherapy (RT) can alter tumor cell biology to make them more aggressive than non-irradiated cells [<xref rid="B108-cancers-12-00743" ref-type="bibr">108</xref>,<xref rid="B109-cancers-12-00743" ref-type="bibr">109</xref>,<xref rid="B110-cancers-12-00743" ref-type="bibr">110</xref>,<xref rid="B111-cancers-12-00743" ref-type="bibr">111</xref>,<xref rid="B112-cancers-12-00743" ref-type="bibr">112</xref>,<xref rid="B113-cancers-12-00743" ref-type="bibr">113</xref>,<xref rid="B114-cancers-12-00743" ref-type="bibr">114</xref>,<xref rid="B115-cancers-12-00743" ref-type="bibr">115</xref>]. In addition to altering cancer cell phenotype, radiation may promote the release of cells into the circulation due to radiation-induced structural damage to blood vessels within the tumors. Furthermore, radiation can induce changes in global signaling such as alterations to cytokines. Granulocyte-macrophage colony stimulating factor (GM-CSF) induced upon irradiation is one cytokine that stimulates tumor self-seeding [<xref rid="B116-cancers-12-00743" ref-type="bibr">116</xref>]. &#x0201c;Tumor self-seeding,&#x0201d; where CTCs in the blood can re-colonize back at the original site has been documented in breast cancer, colon cancer, and melanoma tumors in mice resulting in accelerated tumor and angiogenesis. It has been reported that about half of the breast cancer patients after RT, have recurrence disease at the same site [<xref rid="B117-cancers-12-00743" ref-type="bibr">117</xref>]. Although this tumor recurrence is not entirely due to CTCs, these observations suggest that CTCs play dual roles in tumor dissemination and tumor recurrence after radiation. There is some evidence to support radiation promoting metastasis, however there are extremely limited studies aimed to determine whether RT directly promotes tumor cell release. Martin et al. [<xref rid="B118-cancers-12-00743" ref-type="bibr">118</xref>] sought to determine whether radiotherapy could mobilize viable NSCLC cells into patients&#x02019; circulation. Of the 27 initial patients with locoregional advanced or metastatic disease, 7 of 9 treated with palliative RT had increased CTCs 24 h after the first RT fraction compared to their pretreatment baseline. As previously mentioned, CTCs can clear within minutes after release into the bloodstream. Future studies of CTC counts following radiation at time points within the first 24 h of RT are of interest. However, differences were detected and perhaps tumor cells continue to be shed hours after RT. For another 4 of 8 patients treated with curative-intent RT, CTCs also increased. Collected CTCs exhibited elevated &#x003b3;-H2AX levels consistent with exposure to high doses of ionizing radiation which indicated that they originated from within an RT-treated tumor. The CTCs isolated in this study were proven to be viable as they were positive for Ki67 staining, a marker of proliferation, and the ability to propagate in vitro. The authors conclude that perhaps RT is successful because of high cumulative dose of radiation, but in the early stages of radiotherapy, up to one half of irradiated tumor cells may escape to the circulation. The authors also noted the presence of CTC clusters collected in some patients after RT, even though these clusters were initially absent in the same patient during initial blood draw. The idea that RT may induce the release of small pieces of the tumor into the vasculature is of additional concern as CTC clusters (2&#x02013;50 cells) have been shown to have increased metastatic potential by 23&#x02013;50 fold [<xref rid="B67-cancers-12-00743" ref-type="bibr">67</xref>]. Conversely, another pilot study concluded that RT reduced CTC counts [<xref rid="B119-cancers-12-00743" ref-type="bibr">119</xref>]. Here, blood was collected from patients with localized NSCLC before and one-half to two-thirds through each patient&#x02019;s RT course. In 14 of the 15 patients, CTC counts dropped to below the detectable threshold. The exception was one patient who was found to have developed metastatic disease soon after RT completion. The opposing outcomes in the above studies may be explained by the fact that one group specifically examined the effects of RT in more advanced NSCLC compared to the other. These conflicting findings enhance the need to better understand the biology underlying CTCs and the impact of timing cancer treatments.</p><p>While we still need to determine whether radiotherapy increases CTCs, if the CTCs are viable, and if it is the initial release of CTCs that ultimately promote metastases, a meta-analysis completed using 2 large cohorts of early breast cancer patients concluded that radiotherapy results in positive patient outcomes [<xref rid="B120-cancers-12-00743" ref-type="bibr">120</xref>]. In the first cohort (1697 patients), the 4-year OS for CTC- positive patients who received RT was 94.9% while those who did not receive RT was 88.0%. RT did not affect the 4-year OS for the CTC-negative group (RT treated non-CTC patients = 93.9% vs non-treated non-CTC patients = 93.4%). RT was also associated with longer OS for the CTC-positive patients, but not in the patients without CTCs. Examining a second cohort (1516 patients), the 5-year DFS was better for patients treated with RT, with or without CTCs at time of treatment (88.0% for CTC-positive with RT vs. 75.2% CTC-positive without RT; 92.3% CTC-negative with RT vs. 88.3% CTC-negative without RT). In this second cohort, RT was also associated with longer local recurrence free survival, DFS, and OS. There are conflicting results between these large cohorts. We need a better understanding of CTC biology and how radiotherapy may affect CTCs. Perhaps determining molecular profiles of CTCs and/or tumors will aid in determining the susceptibility of individual&#x02019;s disease to radiotherapy. In any case, additional studies with more patients with different types of cancers and different doses of radiation will need to be completed to make any conclusions about CTC release, metastasis, and overall survival.</p></sec><sec id="sec4dot3-cancers-12-00743"><title>4.3. Chemotherapy </title><p>CTC reduction during and after courses of different chemotherapies is associated with a favorable treatment response and improved survival [<xref rid="B121-cancers-12-00743" ref-type="bibr">121</xref>,<xref rid="B122-cancers-12-00743" ref-type="bibr">122</xref>,<xref rid="B123-cancers-12-00743" ref-type="bibr">123</xref>,<xref rid="B124-cancers-12-00743" ref-type="bibr">124</xref>,<xref rid="B125-cancers-12-00743" ref-type="bibr">125</xref>], while an increase may indicate loss of therapeutic benefit [<xref rid="B74-cancers-12-00743" ref-type="bibr">74</xref>,<xref rid="B75-cancers-12-00743" ref-type="bibr">75</xref>,<xref rid="B126-cancers-12-00743" ref-type="bibr">126</xref>]. However, as in the case with the other treatment modalities, some chemotherapies have been linked to an increase in metastasis. For example, angiogenic inhibitors have not been as effective for improving the survival of patients [<xref rid="B127-cancers-12-00743" ref-type="bibr">127</xref>]. Animal models have shown that although angiogenic inhibitors are successful in reducing the primary tumor [<xref rid="B122-cancers-12-00743" ref-type="bibr">122</xref>,<xref rid="B123-cancers-12-00743" ref-type="bibr">123</xref>], inhibitors such as sunitinib, sorafenib, and SU10944, can induce hypoxia in the residual tumor promoting invasion and metastasis. Another targeted therapy that has been shown to induce metastases in animals is BRAF inhibitors. While vermurafenib treated tumors originating from implanted human melanoma cells were growth inhibited, the vermurafenib-sensitive cells secreted factors which promoted the growth and metastases of vermurafenib-resistant tumors [<xref rid="B128-cancers-12-00743" ref-type="bibr">128</xref>]. PLX4720, another BRAF inhibitor, increased lung, liver, and kidney metastasis of RAS mutant melanoma in mice. Although androgen deprivation therapies have been shown to reduce prostate cancer size, they too may lead to increased metastases in some patients [<xref rid="B129-cancers-12-00743" ref-type="bibr">129</xref>], as both Casodex (bicalutamide) and MDV3100 (enzalutamide) were shown to also increase metastasis in mice. Paclitaxel was shown to promote breast cancer metastasis by increasing local and systemic inflammation, expansion of tumor vascular networks, thus increasing lymphatic metastasis of TLR4-positive tumors [<xref rid="B130-cancers-12-00743" ref-type="bibr">130</xref>]. Everolimus, an mTOR inhibitor, increased the occurrence of distant metastases in a rat model of pancreatic cancer [<xref rid="B131-cancers-12-00743" ref-type="bibr">131</xref>], and cyclophosphamide has been shown to promote metastasis under certain conditions [<xref rid="B132-cancers-12-00743" ref-type="bibr">132</xref>,<xref rid="B133-cancers-12-00743" ref-type="bibr">133</xref>,<xref rid="B134-cancers-12-00743" ref-type="bibr">134</xref>,<xref rid="B135-cancers-12-00743" ref-type="bibr">135</xref>]. </p><p>A possible explanation for the increase in metastases as a result postoperative or adjuvant chemotherapy is that some chemotherapies may render distant tissues more prone to metastatic seeding as a result of a systematic release of cytokines [<xref rid="B136-cancers-12-00743" ref-type="bibr">136</xref>,<xref rid="B137-cancers-12-00743" ref-type="bibr">137</xref>]. Another possible explanation is that chemotherapies may inadvertently promote CTC release, or changes in the population of CTCs released, which in turn may promote or exacerbate metastasis. There are few studies examining whether increases in CTCs and/or changes in CTC biology could possibly be a direct result of therapy. An analysis of CTCs from 10 breast cancer patients pre- and post-treatment was completed [<xref rid="B66-cancers-12-00743" ref-type="bibr">66</xref>], and in the 5 patients who responded to treatment, there was a decrease in total CTCs, but also a shift in EMT characteristics of the CTCs detected. The remaining CTCs detected after treatment were less mesenchymal when characterized with commonly used markers. In contrast, the 5 patients whose disease progressed while on therapy had an increase number in the mesenchymal CTCs. In this study, one patient initially responded to therapy, developed resistance, and then transiently responded to treatment. CTCs were monitored throughout this process and more mesenchymal CTCs tracked with nonresponse. Initially, the mesenchymal CTCs dropped and predominantly switched to CTCs with more epithelial markers, but upon disease progression, the CTCs switched back, presenting more mesenchymal markers. While this study did not answer whether chemotherapy directly promotes CTCs, it did begin to highlight the presence of different cellular markers and differing populations of CTCs, implicating the role of EMT in human breast cancer specimens. A different group examining another set of patients (27) with invasive breast cancer revealed that chemotherapy caused significant changes in CTCs collected [<xref rid="B138-cancers-12-00743" ref-type="bibr">138</xref>]. Some patients experienced an increase in total CTCs as well as an increase in EpCAM<sup>&#x02212;</sup>CD45<sup>&#x02212;</sup>CD44<sup>+</sup>CD24<sup>&#x02212;</sup>N-cadherin<sup>+/&#x02212;</sup> cells, but no changes in the EpCAM<sup>+</sup>CD45<sup>&#x02212;</sup>CD44<sup>+/&#x02212;</sup>CD24<sup>&#x02212;</sup>N-cadherin<sup>+/&#x02212;</sup> population. The only major differences in the populations is the presence or absence of EpCAM, the absence of which indicates a shift in CTCs from epithelial to more mesenchymal phenotype. Similarly, a third study examined CTCs from 62 metastatic breast cancer patients before and after chemotherapy [<xref rid="B139-cancers-12-00743" ref-type="bibr">139</xref>]. The nonresponders to chemotherapy had an increase in CTCs with a cancer stem-like phenotype and partial EMT, suggesting the type of CTC detected in this study is resistant to the therapy. It would appear from these preliminary studies, chemotherapy may not induce CTC release, but rather select for more dangerous tumor cells (i.e., partial EMT and/or more cancer stem-like) potentially resistant to chemotherapy. Along similar lines, studies from our group have shown that chemotherapy [<xref rid="B140-cancers-12-00743" ref-type="bibr">140</xref>], as well as cells which have undergone a partial EMT [<xref rid="B141-cancers-12-00743" ref-type="bibr">141</xref>,<xref rid="B142-cancers-12-00743" ref-type="bibr">142</xref>,<xref rid="B143-cancers-12-00743" ref-type="bibr">143</xref>] or exhibit more stem-like character, have an enhanced ability to reattach after suspension via novel tubulin-driven membrane protrusions termed microtentacles, a possible mechanism for increased metastases.</p><p>Studies directly examining the effect of chemotherapy on mobilization of CTCs are scarce. However, we have identified two studies which concluded chemotherapies can induce CTC release into the bloodstream. Micro-anatomically structures named tumor microenvironment of metastasis (TMEM) within the tumors have been shown to aid in tumor cell intravasation [<xref rid="B144-cancers-12-00743" ref-type="bibr">144</xref>,<xref rid="B145-cancers-12-00743" ref-type="bibr">145</xref>], and their presence has been associated with murine mammary tumor and human breast cancer metastasis [<xref rid="B146-cancers-12-00743" ref-type="bibr">146</xref>,<xref rid="B147-cancers-12-00743" ref-type="bibr">147</xref>]. The three components of a TMEM are a perivascular macrophage, an endothelial cell, and a tumor cell expressing invasive isoforms of the actin-regulatory protein MENA in close proximity to the endothelial cell. Although randomized prospective studies demonstrating that the neoadjuvant use of paclitaxel therapy increased the rate of complete pathological response, it did not improve overall survival [<xref rid="B148-cancers-12-00743" ref-type="bibr">148</xref>,<xref rid="B149-cancers-12-00743" ref-type="bibr">149</xref>]. Since paclitaxel promotes the influx of macrophages into the primary tumor and these cells are required for TMEM assembly [<xref rid="B150-cancers-12-00743" ref-type="bibr">150</xref>,<xref rid="B151-cancers-12-00743" ref-type="bibr">151</xref>], Karagiannis et al. [<xref rid="B152-cancers-12-00743" ref-type="bibr">152</xref>] hypothesized that paclitaxel treatment may increase TMEM sites, leading to an induction of CTCs. Using intravital imaging of mouse mammary tumors in murine models, patient derived xenografts, and fixed human breast cancer tissue, they were able to elucidate mechanisms by which paclitaxel may enhance the dissemination of CTCs. First, paclitaxel increases the infiltration of TIE2<sup>hi</sup>/VEGF<sup>hi</sup> macrophages promoting the formation of more TMEM sites. Second, paclitaxel increases the frequency of functional TMEM sites where increased vascular permeability is achieved by transient vessel &#x0201c;bursting.&#x0201d; Third, it was determined that paclitaxel induced expression of the more invasive MENA isoforms resulting in an increase in tumor cells invasion. In all models examined, paclitaxel treatment increased the number of CTCs by approximately 2-fold. Further examination of the lungs revealed an increased incidence and number of micrometastases in the treated mice, likely as a result of the increase in CTCs. Additional studies into the effect of chemotherapies on TMEMs revealed a doxorubicin/cyclophosphamide combination therapy affects TMEM density, TMEM activity, and CTCs similar to paclitaxel. Chang et al. [<xref rid="B153-cancers-12-00743" ref-type="bibr">153</xref>] were unable to verify an increased infiltration of macrophages (TIE2<sup>+</sup>) within the tumors in their model, but instead showed that the isolated infiltrating macrophages from mice treated with paclitaxel simulated cancer cell invasion more efficiently than the tumor infiltrated macrophages isolated from the untreated mice tumors. They confirm that paclitaxel increases TMEM density and CTCs and established that effect of paclitaxel <italic>in vivo</italic> are due to host-<italic>Aft3</italic> status. Wild-type mice had more CTCs than the <italic>Atf3</italic>-KO mice which was exacerbated by paclitaxel in the WT mice but not in the <italic>Atf3</italic>-KO mice. The complex effect specific chemotherapeutics may play in modulating CTCs still needs to be studied more extensively, but these preliminary studies suggest that the global intervention of chemotherapy may have unintended effects.</p></sec></sec><sec id="sec5-cancers-12-00743"><title>5. Potential Therapies to Reduce CTCs</title><p>Inhibiting cancer progression by preventing dissemination and the emergence of overt metastases is not a new concept. To prevent regrowth at the primary site or growth of overt metastases, adjuvant chemotherapy may be prescribed. For example, targeted therapies such as tamoxifen and aromatase inhibitors are given to breast cancer patients to prevent or delay relapse even when no disease is detectable. The goal of these therapies is to kill or arrest disseminated cancer [<xref rid="B154-cancers-12-00743" ref-type="bibr">154</xref>]. As our understanding of CTC biology and detection methods (i.e., liquid biopsies) for CTCs advance, it is plausible to develop agents specifically targeted to CTC destruction. Since CTCs are suspended in the bloodstream, it can be imagined that these cells are undergoing a multidirectional wound response in which they can experience imbalances between microtubule extension and actin contraction [<xref rid="B142-cancers-12-00743" ref-type="bibr">142</xref>,<xref rid="B155-cancers-12-00743" ref-type="bibr">155</xref>]. Our group has demonstrated that detached cancer cells promote dynamic tubulin-driven protrusions, termed microtentacles, which aid in endothelial cells attachment [<xref rid="B140-cancers-12-00743" ref-type="bibr">140</xref>,<xref rid="B141-cancers-12-00743" ref-type="bibr">141</xref>,<xref rid="B143-cancers-12-00743" ref-type="bibr">143</xref>,<xref rid="B156-cancers-12-00743" ref-type="bibr">156</xref>,<xref rid="B157-cancers-12-00743" ref-type="bibr">157</xref>,<xref rid="B158-cancers-12-00743" ref-type="bibr">158</xref>,<xref rid="B159-cancers-12-00743" ref-type="bibr">159</xref>,<xref rid="B160-cancers-12-00743" ref-type="bibr">160</xref>,<xref rid="B161-cancers-12-00743" ref-type="bibr">161</xref>]. It is hypothesized that repurposing cytoskeletal targeted drugs, frequently used to inhibit growth, and/or developing drug which more specifically target tubulin post-translational modifications, may inhibit microtentacles [<xref rid="B155-cancers-12-00743" ref-type="bibr">155</xref>]. Reducing microtentacle formation may reduce initial endothelial cell engagement promoting CTCs to remain in the bloodstream and die by shear stress or fragmentation (<xref ref-type="fig" rid="cancers-12-00743-f001">Figure 1</xref>). Another strategy would be to target the tumor-associated macrophages, which cause transient permeability to the vasculature [<xref rid="B150-cancers-12-00743" ref-type="bibr">150</xref>], to reduce the number of CTCs. Karagiannis at al. used rebastanib, a TIE2 inhibitor, to target TMEM-associated macrophages. While rebastanib treatment did not affect the overall TMEM number or density of tumor infiltrating macrophages, it did significantly decrease the number of CTCs, indicating that TMEM activity was inhibited [<xref rid="B152-cancers-12-00743" ref-type="bibr">152</xref>]. Once in the bloodstream, CTCs may bind to platelets to avoid leukocyte attack [<xref rid="B162-cancers-12-00743" ref-type="bibr">162</xref>,<xref rid="B163-cancers-12-00743" ref-type="bibr">163</xref>] and the CTC-platelet aggregates may release cytokines which can attract granulocytes [<xref rid="B164-cancers-12-00743" ref-type="bibr">164</xref>]. Targeting the CTC-platelet-granulocyte interaction may also lead to the reduction in CTCs [<xref rid="B164-cancers-12-00743" ref-type="bibr">164</xref>,<xref rid="B165-cancers-12-00743" ref-type="bibr">165</xref>]. Finally, Gkountela et al. have identified six FDA-approved compounds with the ability to reduce CTC clustering ability and suppress spontaneous metastasis in xenograft models [<xref rid="B166-cancers-12-00743" ref-type="bibr">166</xref>]. </p></sec><sec sec-type="conclusions" id="sec6-cancers-12-00743"><title>6. Conclusions </title><p>Importantly, none of the current treatments should be abandoned since the prognostic benefit of these procedures and therapies still strongly outweigh their possible negative effects. Future studies are needed to determine what extent surgical techniques and manipulation, radiotherapy, and chemotherapy have on CTC shedding, biology, and cancer recurrence rates. With approximately 90% of cancer patients dying from metastatic disease, we are hopefully experiencing a shift in cancer research to preventing and eradicating metastasis [<xref rid="B1-cancers-12-00743" ref-type="bibr">1</xref>,<xref rid="B167-cancers-12-00743" ref-type="bibr">167</xref>,<xref rid="B168-cancers-12-00743" ref-type="bibr">168</xref>]. As the ability to detect and characterize CTCs from patients rapidly evolves, we believe that more efforts should be dedicated to understanding the effects of already established interventions and new treatment strategies on CTC number and metastatic efficiency. As the frontier of CTC research continues to expand, the complex underlying biology involved in the metastatic cascade will be clarified. We hope that with these clarifications will come new therapeutics which effectively target CTCs and drivers of metastasis, leading to additional improvements in patient outcomes. </p></sec></body><back><notes><title>Author Contributions</title><p>S.S.M. and M.I.V. conceived and designed the manuscript, T.J.M., K.T.C., S.S.M. and M.I.V. all aided in the original draft preparation, review, and editing. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was supported in part by the National Institutes of Health (R01-CA-124704, R01-CA154624) and the Veterans Administration (BX002746) (S.S.M.) and American Cancer Society (RSG-18-028-01-CSM) (M.I.V.).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-cancers-12-00743"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steeg</surname><given-names>P.S.</given-names></name></person-group><article-title>Targeting metastasis</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>201</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.25</pub-id><pub-id pub-id-type="pmid">27009393</pub-id></element-citation></ref><ref id="B2-cancers-12-00743"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momma</surname><given-names>T.</given-names></name><name><surname>Hamblin</surname><given-names>M.R.</given-names></name><name><surname>Wu</surname><given-names>H.C.</given-names></name><name><surname>Hasan</surname><given-names>T.</given-names></name></person-group><article-title>Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: Local control and distant metastasis</article-title><source>Cancer Res.</source><year>1998</year><volume>58</volume><fpage>5425</fpage><lpage>5431</lpage><?supplied-pmid 9850075?><pub-id pub-id-type="pmid">9850075</pub-id></element-citation></ref><ref id="B3-cancers-12-00743"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldfarb</surname><given-names>Y.</given-names></name><name><surname>Ben-Eliyahu</surname><given-names>S.</given-names></name></person-group><article-title>Surgery as a risk factor for breast cancer recurrence and metastasis: Mediating mechanisms and clinical prophylactic approaches</article-title><source>Breast Dis.</source><year>2006</year><volume>26</volume><fpage>99</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.3233/BD-2007-26109</pub-id><?supplied-pmid 17473369?><pub-id pub-id-type="pmid">17473369</pub-id></element-citation></ref><ref id="B4-cancers-12-00743"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>R.Y.</given-names></name><name><surname>Yao</surname><given-names>Q.Y.</given-names></name><name><surname>Wu</surname><given-names>L.M.</given-names></name><name><surname>Xu</surname><given-names>J.R.</given-names></name></person-group><article-title>Breast Lesions: Diagnosis Using Diffusion Weighted Imaging at 1.5T and 3.0T-Systematic Review and Meta-Analysis</article-title><source>Clin. Breast Cancer</source><year>2018</year><volume>18</volume><fpage>e305</fpage><lpage>e320</lpage><pub-id pub-id-type="doi">10.1016/j.clbc.2017.06.011</pub-id><?supplied-pmid 28802529?><pub-id pub-id-type="pmid">28802529</pub-id></element-citation></ref><ref id="B5-cancers-12-00743"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Galvan</surname><given-names>Y.A.</given-names></name><name><surname>Cardona-Huerta</surname><given-names>S.</given-names></name><name><surname>Ibarra-Fombona</surname><given-names>E.</given-names></name><name><surname>Elizondo-Riojas</surname><given-names>G.</given-names></name></person-group><article-title>Apparent diffusion coefficient (ADC) value to evaluate BI-RADS 4 breast lesions: Correlation with pathological findings</article-title><source>Clin. Imaging</source><year>2015</year><volume>39</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.clinimag.2014.09.015</pub-id><pub-id pub-id-type="pmid">25457520</pub-id></element-citation></ref><ref id="B6-cancers-12-00743"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>J.</given-names></name></person-group><article-title>Angiogenesis</article-title><source>Annu. Rev. Med.</source><year>2006</year><volume>57</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.57.121304.131306</pub-id><pub-id pub-id-type="pmid">16409133</pub-id></element-citation></ref><ref id="B7-cancers-12-00743"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>T.P.</given-names></name><name><surname>Gullino</surname><given-names>P.M.</given-names></name></person-group><article-title>Quantitation of cell shedding into efferent blood of mammary adenocarcinoma</article-title><source>Cancer Res.</source><year>1975</year><volume>35</volume><fpage>512</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">1090362</pub-id></element-citation></ref><ref id="B8-cancers-12-00743"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>A.F.</given-names></name><name><surname>Groom</surname><given-names>A.C.</given-names></name><name><surname>MacDonald</surname><given-names>I.C.</given-names></name></person-group><article-title>Dissemination and growth of cancer cells in metastatic sites</article-title><source>Nat. Rev. Cancer</source><year>2002</year><volume>2</volume><fpage>563</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1038/nrc865</pub-id><pub-id pub-id-type="pmid">12154349</pub-id></element-citation></ref><ref id="B9-cancers-12-00743"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>I.J.</given-names></name></person-group><article-title>Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2&#x02019;-deoxyuridine</article-title><source>J. Natl. Cancer Inst.</source><year>1970</year><volume>45</volume><fpage>773</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">5513503</pub-id></element-citation></ref><ref id="B10-cancers-12-00743"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luzzi</surname><given-names>K.J.</given-names></name><name><surname>MacDonald</surname><given-names>I.C.</given-names></name><name><surname>Schmidt</surname><given-names>E.E.</given-names></name><name><surname>Kerkvliet</surname><given-names>N.</given-names></name><name><surname>Morris</surname><given-names>V.L.</given-names></name><name><surname>Chambers</surname><given-names>A.F.</given-names></name><name><surname>Groom</surname><given-names>A.C.</given-names></name></person-group><article-title>Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases</article-title><source>Am. J. Pathol.</source><year>1998</year><volume>153</volume><fpage>865</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65628-3</pub-id><pub-id pub-id-type="pmid">9736035</pub-id></element-citation></ref><ref id="B11-cancers-12-00743"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coumans</surname><given-names>F.A.</given-names></name><name><surname>Siesling</surname><given-names>S.</given-names></name><name><surname>Terstappen</surname><given-names>L.W.</given-names></name></person-group><article-title>Detection of cancer before distant metastasis</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><elocation-id>283</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-13-283</pub-id><?supplied-pmid 23763955?><pub-id pub-id-type="pmid">23763955</pub-id></element-citation></ref><ref id="B12-cancers-12-00743"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van&#x02019;t Veer</surname><given-names>L.J.</given-names></name><name><surname>Dai</surname><given-names>H.</given-names></name><name><surname>van de Vijver</surname><given-names>M.J.</given-names></name><name><surname>He</surname><given-names>Y.D.</given-names></name><name><surname>Hart</surname><given-names>A.A.</given-names></name><name><surname>Mao</surname><given-names>M.</given-names></name><name><surname>Peterse</surname><given-names>H.L.</given-names></name><name><surname>van der Kooy</surname><given-names>K.</given-names></name><name><surname>Marton</surname><given-names>M.J.</given-names></name><name><surname>Witteveen</surname><given-names>A.T.</given-names></name><etal/></person-group><article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title><source>Nature</source><year>2002</year><volume>415</volume><fpage>530</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1038/415530a</pub-id><?supplied-pmid 11823860?><pub-id pub-id-type="pmid">11823860</pub-id></element-citation></ref><ref id="B13-cancers-12-00743"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van de Vijver</surname><given-names>M.J.</given-names></name><name><surname>He</surname><given-names>Y.D.</given-names></name><name><surname>van&#x02019;t Veer</surname><given-names>L.J.</given-names></name><name><surname>Dai</surname><given-names>H.</given-names></name><name><surname>Hart</surname><given-names>A.A.</given-names></name><name><surname>Voskuil</surname><given-names>D.W.</given-names></name><name><surname>Schreiber</surname><given-names>G.J.</given-names></name><name><surname>Peterse</surname><given-names>J.L.</given-names></name><name><surname>Roberts</surname><given-names>C.</given-names></name><name><surname>Marton</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>A gene-expression signature as a predictor of survival in breast cancer</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>347</volume><fpage>1999</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021967</pub-id><pub-id pub-id-type="pmid">12490681</pub-id></element-citation></ref><ref id="B14-cancers-12-00743"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weigelt</surname><given-names>B.</given-names></name><name><surname>Glas</surname><given-names>A.M.</given-names></name><name><surname>Wessels</surname><given-names>L.F.</given-names></name><name><surname>Witteveen</surname><given-names>A.T.</given-names></name><name><surname>Peterse</surname><given-names>J.L.</given-names></name><name><surname>van&#x02019;t Veer</surname><given-names>L.J.</given-names></name></person-group><article-title>Gene expression profiles of primary breast tumors maintained in distant metastases</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>15901</fpage><lpage>15905</lpage><pub-id pub-id-type="doi">10.1073/pnas.2634067100</pub-id><?supplied-pmid 14665696?><pub-id pub-id-type="pmid">14665696</pub-id></element-citation></ref><ref id="B15-cancers-12-00743"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernards</surname><given-names>R.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>A progression puzzle</article-title><source>Nature</source><year>2002</year><volume>418</volume><fpage>823</fpage><pub-id pub-id-type="doi">10.1038/418823a</pub-id><?supplied-pmid 12192390?><pub-id pub-id-type="pmid">12192390</pub-id></element-citation></ref><ref id="B16-cancers-12-00743"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Husemann</surname><given-names>Y.</given-names></name><name><surname>Geigl</surname><given-names>J.B.</given-names></name><name><surname>Schubert</surname><given-names>F.</given-names></name><name><surname>Musiani</surname><given-names>P.</given-names></name><name><surname>Meyer</surname><given-names>M.</given-names></name><name><surname>Burghart</surname><given-names>E.</given-names></name><name><surname>Forni</surname><given-names>G.</given-names></name><name><surname>Eils</surname><given-names>R.</given-names></name><name><surname>Fehm</surname><given-names>T.</given-names></name><name><surname>Riethmuller</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Systemic spread is an early step in breast cancer</article-title><source>Cancer Cell</source><year>2008</year><volume>13</volume><fpage>58</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.12.003</pub-id><pub-id pub-id-type="pmid">18167340</pub-id></element-citation></ref><ref id="B17-cancers-12-00743"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larson</surname><given-names>C.J.</given-names></name><name><surname>Moreno</surname><given-names>J.G.</given-names></name><name><surname>Pienta</surname><given-names>K.J.</given-names></name><name><surname>Gross</surname><given-names>S.</given-names></name><name><surname>Repollet</surname><given-names>M.</given-names></name><name><surname>O&#x02019;Hara</surname><given-names>S.M.</given-names></name><name><surname>Russell</surname><given-names>T.</given-names></name><name><surname>Terstappen</surname><given-names>L.W.</given-names></name></person-group><article-title>Apoptosis of circulating tumor cells in prostate cancer patients</article-title><source>Cytom. Part A</source><year>2004</year><volume>62</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.20073</pub-id></element-citation></ref><ref id="B18-cancers-12-00743"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehes</surname><given-names>G.</given-names></name><name><surname>Witt</surname><given-names>A.</given-names></name><name><surname>Kubista</surname><given-names>E.</given-names></name><name><surname>Ambros</surname><given-names>P.F.</given-names></name></person-group><article-title>Circulating breast cancer cells are frequently apoptotic</article-title><source>Am. J. Pathol.</source><year>2001</year><volume>159</volume><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)61667-7</pub-id><pub-id pub-id-type="pmid">11438448</pub-id></element-citation></ref><ref id="B19-cancers-12-00743"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukumura</surname><given-names>D.</given-names></name><name><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization</article-title><source>Microvasc. Res.</source><year>2007</year><volume>74</volume><fpage>72</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.mvr.2007.05.003</pub-id><pub-id pub-id-type="pmid">17560615</pub-id></element-citation></ref><ref id="B20-cancers-12-00743"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoletti</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Muniz</surname><given-names>M.C.</given-names></name><name><surname>Kidwell</surname><given-names>K.M.</given-names></name><name><surname>Aung</surname><given-names>K.</given-names></name><name><surname>Thomas</surname><given-names>D.G.</given-names></name><name><surname>Brown</surname><given-names>M.E.</given-names></name><name><surname>Abramson</surname><given-names>V.G.</given-names></name><name><surname>Irvin</surname><given-names>W.J.</given-names><suffix>Jr.</suffix></name><name><surname>Lin</surname><given-names>N.U.</given-names></name><etal/></person-group><article-title>Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>2771</fpage><lpage>2779</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2781</pub-id><pub-id pub-id-type="pmid">25779948</pub-id></element-citation></ref><ref id="B21-cancers-12-00743"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname><given-names>S.</given-names></name><name><surname>Bendahl</surname><given-names>P.O.</given-names></name><name><surname>Larsson</surname><given-names>A.M.</given-names></name><name><surname>Aaltonen</surname><given-names>K.E.</given-names></name><name><surname>Ryden</surname><given-names>L.</given-names></name></person-group><article-title>Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort</article-title><source>BMC Cancer</source><year>2016</year><volume>16</volume><elocation-id>433</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-016-2406-y</pub-id><?supplied-pmid 27390845?><pub-id pub-id-type="pmid">27390845</pub-id></element-citation></ref><ref id="B22-cancers-12-00743"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>J.M.</given-names></name><name><surname>Krebs</surname><given-names>M.</given-names></name><name><surname>Ward</surname><given-names>T.</given-names></name><name><surname>Morris</surname><given-names>K.</given-names></name><name><surname>Sloane</surname><given-names>R.</given-names></name><name><surname>Blackhall</surname><given-names>F.</given-names></name><name><surname>Dive</surname><given-names>C.</given-names></name></person-group><article-title>Circulating tumor cells, enumeration and beyond</article-title><source>Cancers</source><year>2010</year><volume>2</volume><fpage>1236</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.3390/cancers2021236</pub-id><?supplied-pmid 24281115?><pub-id pub-id-type="pmid">24281115</pub-id></element-citation></ref><ref id="B23-cancers-12-00743"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>A.D.</given-names></name><name><surname>Searson</surname><given-names>P.C.</given-names></name></person-group><article-title>Mitosis-Mediated Intravasation in a Tissue-Engineered Tumor-Microvessel Platform</article-title><source>Cancer Res.</source><year>2017</year><volume>77</volume><fpage>6453</fpage><lpage>6461</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-3279</pub-id><?supplied-pmid 28923855?><pub-id pub-id-type="pmid">28923855</pub-id></element-citation></ref><ref id="B24-cancers-12-00743"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolson</surname><given-names>G.L.</given-names></name></person-group><article-title>Metastatic tumor cell attachment and invasion assay utilizing vascular endothelial cell monolayers</article-title><source>J. Histochem. Cytochem.</source><year>1982</year><volume>30</volume><fpage>214</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1177/30.3.7061823</pub-id><pub-id pub-id-type="pmid">7061823</pub-id></element-citation></ref><ref id="B25-cancers-12-00743"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalluri</surname><given-names>R.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>The basics of epithelial-mesenchymal transition</article-title><source>J. Clin. Investig.</source><year>2009</year><volume>119</volume><fpage>1420</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1172/JCI39104</pub-id><pub-id pub-id-type="pmid">19487818</pub-id></element-citation></ref><ref id="B26-cancers-12-00743"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>M.A.</given-names></name><name><surname>Huang</surname><given-names>R.Y.</given-names></name><name><surname>Jackson</surname><given-names>R.A.</given-names></name><name><surname>Thiery</surname><given-names>J.P.</given-names></name></person-group><article-title>Emt: 2016</article-title><source>Cell</source><year>2016</year><volume>166</volume><fpage>21</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.028</pub-id><pub-id pub-id-type="pmid">27368099</pub-id></element-citation></ref><ref id="B27-cancers-12-00743"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiery</surname><given-names>J.P.</given-names></name></person-group><article-title>Epithelial-mesenchymal transitions in tumour progression</article-title><source>Nat. Rev. Cancer</source><year>2002</year><volume>2</volume><fpage>442</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nrc822</pub-id><pub-id pub-id-type="pmid">12189386</pub-id></element-citation></ref><ref id="B28-cancers-12-00743"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>A.W.</given-names></name><name><surname>Pattabiraman</surname><given-names>D.R.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Emerging Biological Principles of Metastasis</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>670</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.11.037</pub-id><pub-id pub-id-type="pmid">28187288</pub-id></element-citation></ref><ref id="B29-cancers-12-00743"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhim</surname><given-names>A.D.</given-names></name><name><surname>Mirek</surname><given-names>E.T.</given-names></name><name><surname>Aiello</surname><given-names>N.M.</given-names></name><name><surname>Maitra</surname><given-names>A.</given-names></name><name><surname>Bailey</surname><given-names>J.M.</given-names></name><name><surname>McAllister</surname><given-names>F.</given-names></name><name><surname>Reichert</surname><given-names>M.</given-names></name><name><surname>Beatty</surname><given-names>G.L.</given-names></name><name><surname>Rustgi</surname><given-names>A.K.</given-names></name><name><surname>Vonderheide</surname><given-names>R.H.</given-names></name><etal/></person-group><article-title>EMT and dissemination precede pancreatic tumor formation</article-title><source>Cell</source><year>2012</year><volume>148</volume><fpage>349</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.11.025</pub-id><pub-id pub-id-type="pmid">22265420</pub-id></element-citation></ref><ref id="B30-cancers-12-00743"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>S.A.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Liao</surname><given-names>M.J.</given-names></name><name><surname>Eaton</surname><given-names>E.N.</given-names></name><name><surname>Ayyanan</surname><given-names>A.</given-names></name><name><surname>Zhou</surname><given-names>A.Y.</given-names></name><name><surname>Brooks</surname><given-names>M.</given-names></name><name><surname>Reinhard</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>C.C.</given-names></name><name><surname>Shipitsin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The epithelial-mesenchymal transition generates cells with properties of stem cells</article-title><source>Cell</source><year>2008</year><volume>133</volume><fpage>704</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.03.027</pub-id><pub-id pub-id-type="pmid">18485877</pub-id></element-citation></ref><ref id="B31-cancers-12-00743"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morel</surname><given-names>A.P.</given-names></name><name><surname>Lievre</surname><given-names>M.</given-names></name><name><surname>Thomas</surname><given-names>C.</given-names></name><name><surname>Hinkal</surname><given-names>G.</given-names></name><name><surname>Ansieau</surname><given-names>S.</given-names></name><name><surname>Puisieux</surname><given-names>A.</given-names></name></person-group><article-title>Generation of breast cancer stem cells through epithelial-mesenchymal transition</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e2888</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0002888</pub-id><?supplied-pmid 18682804?><pub-id pub-id-type="pmid">18682804</pub-id></element-citation></ref><ref id="B32-cancers-12-00743"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>F.</given-names></name><name><surname>Samuel</surname><given-names>S.</given-names></name><name><surname>Evans</surname><given-names>K.W.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Sceusi</surname><given-names>E.</given-names></name><name><surname>Tozzi</surname><given-names>F.</given-names></name><name><surname>Ye</surname><given-names>X.C.</given-names></name><name><surname>Mani</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells</article-title><source>Cancer Med.</source><year>2012</year><volume>1</volume><fpage>5</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1002/cam4.4</pub-id><pub-id pub-id-type="pmid">23342249</pub-id></element-citation></ref><ref id="B33-cancers-12-00743"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>R.</given-names></name><name><surname>Law</surname><given-names>W.L.</given-names></name><name><surname>Chu</surname><given-names>A.C.</given-names></name><name><surname>Poon</surname><given-names>J.T.</given-names></name><name><surname>Lam</surname><given-names>C.S.</given-names></name><name><surname>Chow</surname><given-names>A.K.</given-names></name><name><surname>Ng</surname><given-names>L.</given-names></name><name><surname>Cheung</surname><given-names>L.W.</given-names></name><name><surname>Lan</surname><given-names>X.R.</given-names></name><name><surname>Lan</surname><given-names>H.Y.</given-names></name><etal/></person-group><article-title>A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer</article-title><source>Cell Stem Cell</source><year>2010</year><volume>6</volume><fpage>603</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2010.04.001</pub-id><?supplied-pmid 20569697?><pub-id pub-id-type="pmid">20569697</pub-id></element-citation></ref><ref id="B34-cancers-12-00743"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>H.</given-names></name><name><surname>Xiang</surname><given-names>T.</given-names></name><name><surname>Qi</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>R.</given-names></name><etal/></person-group><article-title>CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>5846</fpage><lpage>5859</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3462</pub-id><?supplied-pmid 25788271?><pub-id pub-id-type="pmid">25788271</pub-id></element-citation></ref><ref id="B35-cancers-12-00743"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasheed</surname><given-names>Z.A.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Kowalski</surname><given-names>J.</given-names></name><name><surname>Freed</surname><given-names>I.</given-names></name><name><surname>Murter</surname><given-names>C.</given-names></name><name><surname>Hong</surname><given-names>S.M.</given-names></name><name><surname>Koorstra</surname><given-names>J.B.</given-names></name><name><surname>Rajeshkumar</surname><given-names>N.V.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma</article-title><source>J. Natl. Cancer Inst.</source><year>2010</year><volume>102</volume><fpage>340</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1093/jnci/djp535</pub-id><?supplied-pmid 20164446?><pub-id pub-id-type="pmid">20164446</pub-id></element-citation></ref><ref id="B36-cancers-12-00743"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>D.</given-names></name><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Sethi</surname><given-names>S.</given-names></name><name><surname>Sarkar</surname><given-names>F.H.</given-names></name></person-group><article-title>Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e12445</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0012445</pub-id><pub-id pub-id-type="pmid">20805998</pub-id></element-citation></ref><ref id="B37-cancers-12-00743"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Kannappan</surname><given-names>V.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Leng</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Xuan</surname><given-names>S.</given-names></name></person-group><article-title>RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma</article-title><source>Exp. Mol. Med.</source><year>2016</year><volume>48</volume><fpage>e238</fpage><pub-id pub-id-type="doi">10.1038/emm.2016.37</pub-id><pub-id pub-id-type="pmid">27282106</pub-id></element-citation></ref><ref id="B38-cancers-12-00743"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bednarz-Knoll</surname><given-names>N.</given-names></name><name><surname>Alix-Panabieres</surname><given-names>C.</given-names></name><name><surname>Pantel</surname><given-names>K.</given-names></name></person-group><article-title>Plasticity of disseminating cancer cells in patients with epithelial malignancies</article-title><source>Cancer Metastasis Rev.</source><year>2012</year><volume>31</volume><fpage>673</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1007/s10555-012-9370-z</pub-id><pub-id pub-id-type="pmid">22733306</pub-id></element-citation></ref><ref id="B39-cancers-12-00743"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosse-Wilde</surname><given-names>A.</given-names></name><name><surname>Fouquier d&#x02019;Herouel</surname><given-names>A.</given-names></name><name><surname>McIntosh</surname><given-names>E.</given-names></name><name><surname>Ertaylan</surname><given-names>G.</given-names></name><name><surname>Skupin</surname><given-names>A.</given-names></name><name><surname>Kuestner</surname><given-names>R.E.</given-names></name><name><surname>del Sol</surname><given-names>A.</given-names></name><name><surname>Walters</surname><given-names>K.A.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name></person-group><article-title>Stemness of the Hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0126522</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0126522</pub-id><pub-id pub-id-type="pmid">26020648</pub-id></element-citation></ref><ref id="B40-cancers-12-00743"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Kang</surname><given-names>Y.</given-names></name></person-group><article-title>Probing the Fifty Shades of EMT in Metastasis</article-title><source>Trends Cancer</source><year>2016</year><volume>2</volume><fpage>65</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2016.01.001</pub-id><pub-id pub-id-type="pmid">27042694</pub-id></element-citation></ref><ref id="B41-cancers-12-00743"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnomet</surname><given-names>A.</given-names></name><name><surname>Syne</surname><given-names>L.</given-names></name><name><surname>Brysse</surname><given-names>A.</given-names></name><name><surname>Feyereisen</surname><given-names>E.</given-names></name><name><surname>Thompson</surname><given-names>E.W.</given-names></name><name><surname>Noel</surname><given-names>A.</given-names></name><name><surname>Foidart</surname><given-names>J.M.</given-names></name><name><surname>Birembaut</surname><given-names>P.</given-names></name><name><surname>Polette</surname><given-names>M.</given-names></name><name><surname>Gilles</surname><given-names>C.</given-names></name></person-group><article-title>A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer</article-title><source>Oncogene</source><year>2012</year><volume>31</volume><fpage>3741</fpage><lpage>3753</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.540</pub-id><?supplied-pmid 22120722?><pub-id pub-id-type="pmid">22120722</pub-id></element-citation></ref><ref id="B42-cancers-12-00743"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trimboli</surname><given-names>A.J.</given-names></name><name><surname>Fukino</surname><given-names>K.</given-names></name><name><surname>de Bruin</surname><given-names>A.</given-names></name><name><surname>Wei</surname><given-names>G.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Tanner</surname><given-names>S.M.</given-names></name><name><surname>Creasap</surname><given-names>N.</given-names></name><name><surname>Rosol</surname><given-names>T.J.</given-names></name><name><surname>Robinson</surname><given-names>M.L.</given-names></name><name><surname>Eng</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Direct evidence for epithelial-mesenchymal transitions in breast cancer</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>937</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2148</pub-id><?supplied-pmid 18245497?><pub-id pub-id-type="pmid">18245497</pub-id></element-citation></ref><ref id="B43-cancers-12-00743"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celia-Terrassa</surname><given-names>T.</given-names></name><name><surname>Meca-Cortes</surname><given-names>O.</given-names></name><name><surname>Mateo</surname><given-names>F.</given-names></name><name><surname>Martinez de Paz</surname><given-names>A.</given-names></name><name><surname>Rubio</surname><given-names>N.</given-names></name><name><surname>Arnal-Estape</surname><given-names>A.</given-names></name><name><surname>Ell</surname><given-names>B.J.</given-names></name><name><surname>Bermudo</surname><given-names>R.</given-names></name><name><surname>Diaz</surname><given-names>A.</given-names></name><name><surname>Guerra-Rebollo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells</article-title><source>J. Clin. Investig.</source><year>2012</year><volume>122</volume><fpage>1849</fpage><lpage>1868</lpage><pub-id pub-id-type="doi">10.1172/JCI59218</pub-id><?supplied-pmid 22505459?><pub-id pub-id-type="pmid">22505459</pub-id></element-citation></ref><ref id="B44-cancers-12-00743"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundgren</surname><given-names>K.</given-names></name><name><surname>Nordenskjold</surname><given-names>B.</given-names></name><name><surname>Landberg</surname><given-names>G.</given-names></name></person-group><article-title>Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer</article-title><source>Br. J. Cancer</source><year>2009</year><volume>101</volume><fpage>1769</fpage><lpage>1781</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605369</pub-id><pub-id pub-id-type="pmid">19844232</pub-id></element-citation></ref><ref id="B45-cancers-12-00743"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>T.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Ta</surname><given-names>C.H.</given-names></name><name><surname>Villarreal-Ponce</surname><given-names>A.</given-names></name><name><surname>Nie</surname><given-names>Q.</given-names></name><name><surname>Dai</surname><given-names>X.</given-names></name></person-group><article-title>An Ovol2-Zeb1 Mutual Inhibitory Circuit Governs Bidirectional and Multi-Step Transition between Epithelial and Mesenchymal States</article-title><source>PLoS Comput. Biol.</source><year>2015</year><volume>11</volume><elocation-id>e1004569</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004569</pub-id><pub-id pub-id-type="pmid">26554584</pub-id></element-citation></ref><ref id="B46-cancers-12-00743"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sampson</surname><given-names>V.B.</given-names></name><name><surname>David</surname><given-names>J.M.</given-names></name><name><surname>Puig</surname><given-names>I.</given-names></name><name><surname>Patil</surname><given-names>P.U.</given-names></name><name><surname>de Herreros</surname><given-names>A.G.</given-names></name><name><surname>Thomas</surname><given-names>G.V.</given-names></name><name><surname>Rajasekaran</surname><given-names>A.K.</given-names></name></person-group><article-title>Wilms&#x02019; tumor protein induces an epithelial-mesenchymal hybrid differentiation state in clear cell renal cell carcinoma</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e102041</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0102041</pub-id><pub-id pub-id-type="pmid">25025131</pub-id></element-citation></ref><ref id="B47-cancers-12-00743"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schliekelman</surname><given-names>M.J.</given-names></name><name><surname>Taguchi</surname><given-names>A.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Dai</surname><given-names>X.</given-names></name><name><surname>Rodriguez</surname><given-names>J.</given-names></name><name><surname>Celiktas</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Chin</surname><given-names>A.</given-names></name><name><surname>Wong</surname><given-names>C.H.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival</article-title><source>Cancer Res.</source><year>2015</year><volume>75</volume><fpage>1789</fpage><lpage>1800</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2535</pub-id><pub-id pub-id-type="pmid">25744723</pub-id></element-citation></ref><ref id="B48-cancers-12-00743"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>P.C.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>Insights on CTC Biology and Clinical Impact Emerging from Advances in Capture Technology</article-title><source>Cells</source><year>2019</year><volume>8</volume><elocation-id>553</elocation-id><pub-id pub-id-type="doi">10.3390/cells8060553</pub-id></element-citation></ref><ref id="B49-cancers-12-00743"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>M.M.</given-names></name><name><surname>Ramani</surname><given-names>V.C.</given-names></name><name><surname>Jeffrey</surname><given-names>S.S.</given-names></name></person-group><article-title>Circulating tumor cell technologies</article-title><source>Mol. Oncol.</source><year>2016</year><volume>10</volume><fpage>374</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2016.01.007</pub-id><pub-id pub-id-type="pmid">26897752</pub-id></element-citation></ref><ref id="B50-cancers-12-00743"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boya</surname><given-names>M.</given-names></name><name><surname>Chu</surname><given-names>C.H.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Ozkaya-Ahmadov</surname><given-names>T.</given-names></name><name><surname>Sarioglu</surname><given-names>A.F.</given-names></name></person-group><article-title>Circulating Tumor Cell Enrichment Technologies</article-title><source>Recent Results Cancer Res.</source><year>2020</year><volume>215</volume><fpage>25</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-26439-0_2</pub-id><pub-id pub-id-type="pmid">31605222</pub-id></element-citation></ref><ref id="B51-cancers-12-00743"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banko</surname><given-names>P.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name><name><surname>Nagygyorgy</surname><given-names>V.</given-names></name><name><surname>Zrinyi</surname><given-names>M.</given-names></name><name><surname>Chae</surname><given-names>C.H.</given-names></name><name><surname>Cho</surname><given-names>D.H.</given-names></name><name><surname>Telekes</surname><given-names>A.</given-names></name></person-group><article-title>Technologies for circulating tumor cell separation from whole blood</article-title><source>J. Hematol. Oncol.</source><year>2019</year><volume>12</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s13045-019-0735-4</pub-id><pub-id pub-id-type="pmid">31088479</pub-id></element-citation></ref><ref id="B52-cancers-12-00743"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Current detection technologies for circulating tumor cells</article-title><source>Chem. Soc. Rev.</source><year>2017</year><volume>46</volume><fpage>2038</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.1039/C6CS00803H</pub-id><?supplied-pmid 28393954?><pub-id pub-id-type="pmid">28393954</pub-id></element-citation></ref><ref id="B53-cancers-12-00743"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawal</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Y.P.</given-names></name><name><surname>Cote</surname><given-names>R.</given-names></name><name><surname>Agarwal</surname><given-names>A.</given-names></name></person-group><article-title>Identification and Quantitation of Circulating Tumor Cells</article-title><source>Annu. Rev. Anal. Chem. (Palo Alto Calif.)</source><year>2017</year><volume>10</volume><fpage>321</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1146/annurev-anchem-061516-045405</pub-id><?supplied-pmid 28301753?><pub-id pub-id-type="pmid">28301753</pub-id></element-citation></ref><ref id="B54-cancers-12-00743"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khetani</surname><given-names>S.</given-names></name><name><surname>Mohammadi</surname><given-names>M.</given-names></name><name><surname>Nezhad</surname><given-names>A.S.</given-names></name></person-group><article-title>Filter-based isolation, enrichment, and characterization of circulating tumor cells</article-title><source>Biotechnol. Bioeng.</source><year>2018</year><volume>115</volume><fpage>2504</fpage><lpage>2529</lpage><pub-id pub-id-type="doi">10.1002/bit.26787</pub-id><?supplied-pmid 29989145?><pub-id pub-id-type="pmid">29989145</pub-id></element-citation></ref><ref id="B55-cancers-12-00743"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>K.J.</given-names></name><name><surname>Gabrielson</surname><given-names>E.</given-names></name><name><surname>Werb</surname><given-names>Z.</given-names></name><name><surname>Ewald</surname><given-names>A.J.</given-names></name></person-group><article-title>Collective invasion in breast cancer requires a conserved basal epithelial program</article-title><source>Cell</source><year>2013</year><volume>155</volume><fpage>1639</fpage><lpage>1651</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.11.029</pub-id><?supplied-pmid 24332913?><pub-id pub-id-type="pmid">24332913</pub-id></element-citation></ref><ref id="B56-cancers-12-00743"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>K.J.</given-names></name><name><surname>Padmanaban</surname><given-names>V.</given-names></name><name><surname>Silvestri</surname><given-names>V.</given-names></name><name><surname>Schipper</surname><given-names>K.</given-names></name><name><surname>Cohen</surname><given-names>J.D.</given-names></name><name><surname>Fairchild</surname><given-names>A.N.</given-names></name><name><surname>Gorin</surname><given-names>M.A.</given-names></name><name><surname>Verdone</surname><given-names>J.E.</given-names></name><name><surname>Pienta</surname><given-names>K.J.</given-names></name><name><surname>Bader</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E854</fpage><lpage>E863</lpage><pub-id pub-id-type="doi">10.1073/pnas.1508541113</pub-id><?supplied-pmid 26831077?><pub-id pub-id-type="pmid">26831077</pub-id></element-citation></ref><ref id="B57-cancers-12-00743"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyckoff</surname><given-names>J.B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>E.Y.</given-names></name><name><surname>Li</surname><given-names>J.F.</given-names></name><name><surname>Goswami</surname><given-names>S.</given-names></name><name><surname>Stanley</surname><given-names>E.R.</given-names></name><name><surname>Segall</surname><given-names>J.E.</given-names></name><name><surname>Pollard</surname><given-names>J.W.</given-names></name><name><surname>Condeelis</surname><given-names>J.</given-names></name></person-group><article-title>Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>2649</fpage><lpage>2656</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1823</pub-id><pub-id pub-id-type="pmid">17363585</pub-id></element-citation></ref><ref id="B58-cancers-12-00743"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>H.</given-names></name><name><surname>Wyckoff</surname><given-names>J.</given-names></name><name><surname>Condeelis</surname><given-names>J.</given-names></name></person-group><article-title>Cell migration in tumors</article-title><source>Curr. Opin. Cell Biol.</source><year>2005</year><volume>17</volume><fpage>559</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2005.08.002</pub-id><pub-id pub-id-type="pmid">16098726</pub-id></element-citation></ref><ref id="B59-cancers-12-00743"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Condeelis</surname><given-names>J.</given-names></name><name><surname>Pollard</surname><given-names>J.W.</given-names></name></person-group><article-title>Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>263</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.01.007</pub-id><pub-id pub-id-type="pmid">16439202</pub-id></element-citation></ref><ref id="B60-cancers-12-00743"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stegner</surname><given-names>D.</given-names></name><name><surname>Dutting</surname><given-names>S.</given-names></name><name><surname>Nieswandt</surname><given-names>B.</given-names></name></person-group><article-title>Mechanistic explanation for platelet contribution to cancer metastasis</article-title><source>Thromb. Res.</source><year>2014</year><volume>133</volume><issue>Suppl. 2</issue><fpage>S149</fpage><lpage>S157</lpage><pub-id pub-id-type="doi">10.1016/S0049-3848(14)50025-4</pub-id><pub-id pub-id-type="pmid">24862136</pub-id></element-citation></ref><ref id="B61-cancers-12-00743"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>I.J.</given-names></name></person-group><article-title>The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis</article-title><source>Eur. J. Cancer</source><year>1973</year><volume>9</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/S0014-2964(73)80022-2</pub-id><pub-id pub-id-type="pmid">4787857</pub-id></element-citation></ref><ref id="B62-cancers-12-00743"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liotta</surname><given-names>L.A.</given-names></name><name><surname>Saidel</surname><given-names>M.G.</given-names></name><name><surname>Kleinerman</surname><given-names>J.</given-names></name></person-group><article-title>The significance of hematogenous tumor cell clumps in the metastatic process</article-title><source>Cancer Res.</source><year>1976</year><volume>36</volume><fpage>889</fpage><lpage>894</lpage><?supplied-pmid 1253177?><pub-id pub-id-type="pmid">1253177</pub-id></element-citation></ref><ref id="B63-cancers-12-00743"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molnar</surname><given-names>B.</given-names></name><name><surname>Ladanyi</surname><given-names>A.</given-names></name><name><surname>Tanko</surname><given-names>L.</given-names></name><name><surname>Sreter</surname><given-names>L.</given-names></name><name><surname>Tulassay</surname><given-names>Z.</given-names></name></person-group><article-title>Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients</article-title><source>Clin. Cancer Res.</source><year>2001</year><volume>7</volume><fpage>4080</fpage><lpage>4085</lpage><?supplied-pmid 11751505?><pub-id pub-id-type="pmid">11751505</pub-id></element-citation></ref><ref id="B64-cancers-12-00743"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>E.H.</given-names></name><name><surname>Wendel</surname><given-names>M.</given-names></name><name><surname>Luttgen</surname><given-names>M.</given-names></name><name><surname>Yoshioka</surname><given-names>C.</given-names></name><name><surname>Marrinucci</surname><given-names>D.</given-names></name><name><surname>Lazar</surname><given-names>D.</given-names></name><name><surname>Schram</surname><given-names>E.</given-names></name><name><surname>Nieva</surname><given-names>J.</given-names></name><name><surname>Bazhenova</surname><given-names>L.</given-names></name><name><surname>Morgan</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors</article-title><source>Phys. Biol.</source><year>2012</year><volume>9</volume><fpage>016001</fpage><pub-id pub-id-type="doi">10.1088/1478-3975/9/1/016001</pub-id><?supplied-pmid 22306705?><pub-id pub-id-type="pmid">22306705</pub-id></element-citation></ref><ref id="B65-cancers-12-00743"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stott</surname><given-names>S.L.</given-names></name><name><surname>Hsu</surname><given-names>C.H.</given-names></name><name><surname>Tsukrov</surname><given-names>D.I.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Miyamoto</surname><given-names>D.T.</given-names></name><name><surname>Waltman</surname><given-names>B.A.</given-names></name><name><surname>Rothenberg</surname><given-names>S.M.</given-names></name><name><surname>Shah</surname><given-names>A.M.</given-names></name><name><surname>Smas</surname><given-names>M.E.</given-names></name><name><surname>Korir</surname><given-names>G.K.</given-names></name><etal/></person-group><article-title>Isolation of circulating tumor cells using a microvortex-generating herringbone-chip</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>18392</fpage><lpage>18397</lpage><pub-id pub-id-type="doi">10.1073/pnas.1012539107</pub-id><?supplied-pmid 20930119?><pub-id pub-id-type="pmid">20930119</pub-id></element-citation></ref><ref id="B66-cancers-12-00743"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Bardia</surname><given-names>A.</given-names></name><name><surname>Wittner</surname><given-names>B.S.</given-names></name><name><surname>Stott</surname><given-names>S.L.</given-names></name><name><surname>Smas</surname><given-names>M.E.</given-names></name><name><surname>Ting</surname><given-names>D.T.</given-names></name><name><surname>Isakoff</surname><given-names>S.J.</given-names></name><name><surname>Ciciliano</surname><given-names>J.C.</given-names></name><name><surname>Wells</surname><given-names>M.N.</given-names></name><name><surname>Shah</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>580</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1126/science.1228522</pub-id><pub-id pub-id-type="pmid">23372014</pub-id></element-citation></ref><ref id="B67-cancers-12-00743"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aceto</surname><given-names>N.</given-names></name><name><surname>Bardia</surname><given-names>A.</given-names></name><name><surname>Miyamoto</surname><given-names>D.T.</given-names></name><name><surname>Donaldson</surname><given-names>M.C.</given-names></name><name><surname>Wittner</surname><given-names>B.S.</given-names></name><name><surname>Spencer</surname><given-names>J.A.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Pely</surname><given-names>A.</given-names></name><name><surname>Engstrom</surname><given-names>A.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis</article-title><source>Cell</source><year>2014</year><volume>158</volume><fpage>1110</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.07.013</pub-id><pub-id pub-id-type="pmid">25171411</pub-id></element-citation></ref><ref id="B68-cancers-12-00743"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Updyke</surname><given-names>T.V.</given-names></name><name><surname>Nicolson</surname><given-names>G.L.</given-names></name></person-group><article-title>Malignant melanoma cell lines selected in vitro for increased homotypic adhesion properties have increased experimental metastatic potential</article-title><source>Clin. Exp. Metastasis</source><year>1986</year><volume>4</volume><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1007/BF00133592</pub-id><pub-id pub-id-type="pmid">3791726</pub-id></element-citation></ref><ref id="B69-cancers-12-00743"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sleeman</surname><given-names>J.P.</given-names></name><name><surname>Nazarenko</surname><given-names>I.</given-names></name><name><surname>Thiele</surname><given-names>W.</given-names></name></person-group><article-title>Do all roads lead to Rome? Routes to metastasis development</article-title><source>Int. J. Cancer</source><year>2011</year><volume>128</volume><fpage>2511</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1002/ijc.26027</pub-id><pub-id pub-id-type="pmid">21365648</pub-id></element-citation></ref><ref id="B70-cancers-12-00743"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roh</surname><given-names>J.</given-names></name><name><surname>Muelleman</surname><given-names>T.</given-names></name><name><surname>Tawfik</surname><given-names>O.</given-names></name><name><surname>Thomas</surname><given-names>S.M.</given-names></name></person-group><article-title>Perineural growth in head and neck squamous cell carcinoma: A review</article-title><source>Oral Oncol.</source><year>2015</year><volume>51</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2014.10.004</pub-id><pub-id pub-id-type="pmid">25456006</pub-id></element-citation></ref><ref id="B71-cancers-12-00743"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchesi</surname><given-names>F.</given-names></name><name><surname>Piemonti</surname><given-names>L.</given-names></name><name><surname>Mantovani</surname><given-names>A.</given-names></name><name><surname>Allavena</surname><given-names>P.</given-names></name></person-group><article-title>Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis</article-title><source>Cytokine Growth Factor Rev.</source><year>2010</year><volume>21</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2009.11.001</pub-id><?supplied-pmid 20060768?><pub-id pub-id-type="pmid">20060768</pub-id></element-citation></ref><ref id="B72-cancers-12-00743"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lugassy</surname><given-names>C.</given-names></name><name><surname>Kleinman</surname><given-names>H.K.</given-names></name><name><surname>Engbring</surname><given-names>J.A.</given-names></name><name><surname>Welch</surname><given-names>D.R.</given-names></name><name><surname>Harms</surname><given-names>J.F.</given-names></name><name><surname>Rufner</surname><given-names>R.</given-names></name><name><surname>Ghanem</surname><given-names>G.</given-names></name><name><surname>Patierno</surname><given-names>S.R.</given-names></name><name><surname>Barnhill</surname><given-names>R.L.</given-names></name></person-group><article-title>Pericyte-like location of GFP-tagged melanoma cells: Ex vivo and in vivo studies of extravascular migratory metastasis</article-title><source>Am. J. Pathol.</source><year>2004</year><volume>164</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)63207-5</pub-id><pub-id pub-id-type="pmid">15039208</pub-id></element-citation></ref><ref id="B73-cancers-12-00743"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>O.A.</given-names></name><name><surname>Anderson</surname><given-names>R.L.</given-names></name><name><surname>Narayan</surname><given-names>K.</given-names></name><name><surname>MacManus</surname><given-names>M.P.</given-names></name></person-group><article-title>Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2017</year><volume>14</volume><fpage>32</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2016.128</pub-id><?supplied-pmid 27550857?><pub-id pub-id-type="pmid">27550857</pub-id></element-citation></ref><ref id="B74-cancers-12-00743"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>S.J.</given-names></name><name><surname>Punt</surname><given-names>C.J.</given-names></name><name><surname>Iannotti</surname><given-names>N.</given-names></name><name><surname>Saidman</surname><given-names>B.H.</given-names></name><name><surname>Sabbath</surname><given-names>K.D.</given-names></name><name><surname>Gabrail</surname><given-names>N.Y.</given-names></name><name><surname>Picus</surname><given-names>J.</given-names></name><name><surname>Morse</surname><given-names>M.</given-names></name><name><surname>Mitchell</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer</article-title><source>J. Clin. Oncol.</source><year>2008</year><volume>26</volume><fpage>3213</fpage><lpage>3221</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.8923</pub-id><?supplied-pmid 18591556?><pub-id pub-id-type="pmid">18591556</pub-id></element-citation></ref><ref id="B75-cancers-12-00743"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristofanilli</surname><given-names>M.</given-names></name><name><surname>Budd</surname><given-names>G.T.</given-names></name><name><surname>Ellis</surname><given-names>M.J.</given-names></name><name><surname>Stopeck</surname><given-names>A.</given-names></name><name><surname>Matera</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>M.C.</given-names></name><name><surname>Reuben</surname><given-names>J.M.</given-names></name><name><surname>Doyle</surname><given-names>G.V.</given-names></name><name><surname>Allard</surname><given-names>W.J.</given-names></name><name><surname>Terstappen</surname><given-names>L.W.</given-names></name><etal/></person-group><article-title>Circulating tumor cells, disease progression, and survival in metastatic breast cancer</article-title><source>N. Engl. J. Med.</source><year>2004</year><volume>351</volume><fpage>781</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa040766</pub-id><pub-id pub-id-type="pmid">15317891</pub-id></element-citation></ref><ref id="B76-cancers-12-00743"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bono</surname><given-names>J.S.</given-names></name><name><surname>Scher</surname><given-names>H.I.</given-names></name><name><surname>Montgomery</surname><given-names>R.B.</given-names></name><name><surname>Parker</surname><given-names>C.</given-names></name><name><surname>Miller</surname><given-names>M.C.</given-names></name><name><surname>Tissing</surname><given-names>H.</given-names></name><name><surname>Doyle</surname><given-names>G.V.</given-names></name><name><surname>Terstappen</surname><given-names>L.W.</given-names></name><name><surname>Pienta</surname><given-names>K.J.</given-names></name><name><surname>Raghavan</surname><given-names>D.</given-names></name></person-group><article-title>Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>6302</fpage><lpage>6309</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0872</pub-id><pub-id pub-id-type="pmid">18829513</pub-id></element-citation></ref><ref id="B77-cancers-12-00743"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mocellin</surname><given-names>S.</given-names></name><name><surname>Del Fiore</surname><given-names>P.</given-names></name><name><surname>Guarnieri</surname><given-names>L.</given-names></name><name><surname>Scalerta</surname><given-names>R.</given-names></name><name><surname>Foletto</surname><given-names>M.</given-names></name><name><surname>Chiarion</surname><given-names>V.</given-names></name><name><surname>Pilati</surname><given-names>P.</given-names></name><name><surname>Nitti</surname><given-names>D.</given-names></name><name><surname>Lise</surname><given-names>M.</given-names></name><name><surname>Rossi</surname><given-names>C.R.</given-names></name></person-group><article-title>Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma</article-title><source>Int. J. Cancer</source><year>2004</year><volume>111</volume><fpage>741</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1002/ijc.20347</pub-id><pub-id pub-id-type="pmid">15252844</pub-id></element-citation></ref><ref id="B78-cancers-12-00743"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>J.G.</given-names></name><name><surname>O&#x02019;Hara</surname><given-names>S.M.</given-names></name><name><surname>Gross</surname><given-names>S.</given-names></name><name><surname>Doyle</surname><given-names>G.</given-names></name><name><surname>Fritsche</surname><given-names>H.</given-names></name><name><surname>Gomella</surname><given-names>L.G.</given-names></name><name><surname>Terstappen</surname><given-names>L.W.</given-names></name></person-group><article-title>Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status</article-title><source>Urology</source><year>2001</year><volume>58</volume><fpage>386</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/S0090-4295(01)01191-8</pub-id><pub-id pub-id-type="pmid">11549486</pub-id></element-citation></ref><ref id="B79-cancers-12-00743"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dalum</surname><given-names>G.</given-names></name><name><surname>van der Stam</surname><given-names>G.J.</given-names></name><name><surname>Tibbe</surname><given-names>A.G.</given-names></name><name><surname>Franken</surname><given-names>B.</given-names></name><name><surname>Mastboom</surname><given-names>W.J.</given-names></name><name><surname>Vermes</surname><given-names>I.</given-names></name><name><surname>de Groot</surname><given-names>M.R.</given-names></name><name><surname>Terstappen</surname><given-names>L.W.</given-names></name></person-group><article-title>Circulating tumor cells before and during follow-up after breast cancer surgery</article-title><source>Int. J. Oncol.</source><year>2015</year><volume>46</volume><fpage>407</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.3892/ijo.2014.2694</pub-id><pub-id pub-id-type="pmid">25339612</pub-id></element-citation></ref><ref id="B80-cancers-12-00743"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahbari</surname><given-names>N.N.</given-names></name><name><surname>Aigner</surname><given-names>M.</given-names></name><name><surname>Thorlund</surname><given-names>K.</given-names></name><name><surname>Mollberg</surname><given-names>N.</given-names></name><name><surname>Motschall</surname><given-names>E.</given-names></name><name><surname>Jensen</surname><given-names>K.</given-names></name><name><surname>Diener</surname><given-names>M.K.</given-names></name><name><surname>Buchler</surname><given-names>M.W.</given-names></name><name><surname>Koch</surname><given-names>M.</given-names></name><name><surname>Weitz</surname><given-names>J.</given-names></name></person-group><article-title>Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>1714</fpage><lpage>1726</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.01.008</pub-id><pub-id pub-id-type="pmid">20100481</pub-id></element-citation></ref><ref id="B81-cancers-12-00743"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinert</surname><given-names>G.</given-names></name><name><surname>Scholch</surname><given-names>S.</given-names></name><name><surname>Koch</surname><given-names>M.</given-names></name><name><surname>Weitz</surname><given-names>J.</given-names></name></person-group><article-title>Biology and significance of circulating and disseminated tumour cells in colorectal cancer</article-title><source>Langenbeck&#x02019;s Arch. Surg.</source><year>2012</year><volume>397</volume><fpage>535</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1007/s00423-012-0917-9</pub-id><pub-id pub-id-type="pmid">22350614</pub-id></element-citation></ref><ref id="B82-cancers-12-00743"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peach</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>C.</given-names></name><name><surname>Zacharakis</surname><given-names>E.</given-names></name><name><surname>Purkayastha</surname><given-names>S.</given-names></name><name><surname>Ziprin</surname><given-names>P.</given-names></name></person-group><article-title>Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: A systematic review</article-title><source>Br. J. Cancer</source><year>2010</year><volume>102</volume><fpage>1327</fpage><lpage>1334</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605651</pub-id><?supplied-pmid 20389297?><pub-id pub-id-type="pmid">20389297</pub-id></element-citation></ref><ref id="B83-cancers-12-00743"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapeleris</surname><given-names>J.</given-names></name><name><surname>Kulasinghe</surname><given-names>A.</given-names></name><name><surname>Warkiani</surname><given-names>M.E.</given-names></name><name><surname>Vela</surname><given-names>I.</given-names></name><name><surname>Kenny</surname><given-names>L.</given-names></name><name><surname>O&#x02019;Byrne</surname><given-names>K.</given-names></name><name><surname>Punyadeera</surname><given-names>C.</given-names></name></person-group><article-title>The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer</article-title><source>Front. Oncol.</source><year>2018</year><volume>8</volume><fpage>311</fpage><pub-id pub-id-type="doi">10.3389/fonc.2018.00311</pub-id><?supplied-pmid 30155443?><pub-id pub-id-type="pmid">30155443</pub-id></element-citation></ref><ref id="B84-cancers-12-00743"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulasinghe</surname><given-names>A.</given-names></name><name><surname>Kapeleris</surname><given-names>J.</given-names></name><name><surname>Kimberley</surname><given-names>R.</given-names></name><name><surname>Mattarollo</surname><given-names>S.R.</given-names></name><name><surname>Thompson</surname><given-names>E.W.</given-names></name><name><surname>Thiery</surname><given-names>J.P.</given-names></name><name><surname>Kenny</surname><given-names>L.</given-names></name><name><surname>O&#x02019;Byrne</surname><given-names>K.</given-names></name><name><surname>Punyadeera</surname><given-names>C.</given-names></name></person-group><article-title>The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer</article-title><source>Cancer Med.</source><year>2018</year><volume>7</volume><fpage>5910</fpage><lpage>5919</lpage><pub-id pub-id-type="doi">10.1002/cam4.1832</pub-id><?supplied-pmid 30565869?><pub-id pub-id-type="pmid">30565869</pub-id></element-citation></ref><ref id="B85-cancers-12-00743"><label>85.</label><element-citation publication-type="web"><article-title>National Breast Cancer Foundation, Inc. Breast Anatomy</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="www.nationalbreastcancer.org">www.nationalbreastcancer.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-09-01">(accessed on 1 September 2019)</date-in-citation></element-citation></ref><ref id="B86-cancers-12-00743"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>R.N.</given-names></name><name><surname>Riba</surname><given-names>R.D.</given-names></name><name><surname>Zacharoulis</surname><given-names>S.</given-names></name><name><surname>Bramley</surname><given-names>A.H.</given-names></name><name><surname>Vincent</surname><given-names>L.</given-names></name><name><surname>Costa</surname><given-names>C.</given-names></name><name><surname>MacDonald</surname><given-names>D.D.</given-names></name><name><surname>Jin</surname><given-names>D.K.</given-names></name><name><surname>Shido</surname><given-names>K.</given-names></name><name><surname>Kerns</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche</article-title><source>Nature</source><year>2005</year><volume>438</volume><fpage>820</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1038/nature04186</pub-id><?supplied-pmid 16341007?><pub-id pub-id-type="pmid">16341007</pub-id></element-citation></ref><ref id="B87-cancers-12-00743"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>E.</given-names></name><name><surname>Wolff</surname><given-names>N.</given-names></name><name><surname>Knuechel</surname><given-names>R.</given-names></name><name><surname>Ruschoff</surname><given-names>J.</given-names></name><name><surname>Hofstaedter</surname><given-names>F.</given-names></name><name><surname>Taeger</surname><given-names>K.</given-names></name></person-group><article-title>Tumor cells in blood shed from the surgical field</article-title><source>Arch. Surg.</source><year>1995</year><volume>130</volume><fpage>387</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1001/archsurg.1995.01430040049007</pub-id><pub-id pub-id-type="pmid">7710337</pub-id></element-citation></ref><ref id="B88-cancers-12-00743"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>M.</given-names></name><name><surname>Tanaka</surname><given-names>F.</given-names></name><name><surname>Yoneda</surname><given-names>K.</given-names></name><name><surname>Takuwa</surname><given-names>T.</given-names></name><name><surname>Matsumoto</surname><given-names>S.</given-names></name><name><surname>Okumura</surname><given-names>Y.</given-names></name><name><surname>Kondo</surname><given-names>N.</given-names></name><name><surname>Tsubota</surname><given-names>N.</given-names></name><name><surname>Tsujimura</surname><given-names>T.</given-names></name><name><surname>Tabata</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer</article-title><source>Interact. Cardiovasc. Thorac. Surg.</source><year>2014</year><volume>18</volume><fpage>775</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1093/icvts/ivu048</pub-id><pub-id pub-id-type="pmid">24618055</pub-id></element-citation></ref><ref id="B89-cancers-12-00743"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papavasiliou</surname><given-names>P.</given-names></name><name><surname>Fisher</surname><given-names>T.</given-names></name><name><surname>Kuhn</surname><given-names>J.</given-names></name><name><surname>Nemunaitis</surname><given-names>J.</given-names></name><name><surname>Lamont</surname><given-names>J.</given-names></name></person-group><article-title>Circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer</article-title><source>Bayl. Univ. Med. Cent. Proc.</source><year>2010</year><volume>23</volume><fpage>11</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1080/08998280.2010.11928572</pub-id></element-citation></ref><ref id="B90-cancers-12-00743"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsutani</surname><given-names>N.</given-names></name><name><surname>Sawabata</surname><given-names>N.</given-names></name><name><surname>Yamaguchi</surname><given-names>M.</given-names></name><name><surname>Woo</surname><given-names>T.</given-names></name><name><surname>Kudo</surname><given-names>Y.</given-names></name><name><surname>Kawase</surname><given-names>A.</given-names></name><name><surname>Shiono</surname><given-names>S.</given-names></name><name><surname>Iinuma</surname><given-names>H.</given-names></name><name><surname>Morita</surname><given-names>S.</given-names></name><name><surname>Kawamura</surname><given-names>M.</given-names></name></person-group><article-title>Does lung cancer surgery cause circulating tumor cells?&#x02014;A multicenter, prospective study</article-title><source>J. Thorac. Dis.</source><year>2017</year><volume>9</volume><fpage>2419</fpage><lpage>2426</lpage><pub-id pub-id-type="doi">10.21037/jtd.2017.07.33</pub-id><pub-id pub-id-type="pmid">28932547</pub-id></element-citation></ref><ref id="B91-cancers-12-00743"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.J.</given-names></name><name><surname>Xiao</surname><given-names>W.</given-names></name><name><surname>Dong</surname><given-names>S.L.</given-names></name><name><surname>Liang</surname><given-names>H.F.</given-names></name><name><surname>Zhang</surname><given-names>Z.W.</given-names></name><name><surname>Zhang</surname><given-names>B.X.</given-names></name><name><surname>Huang</surname><given-names>Z.Y.</given-names></name><name><surname>Chen</surname><given-names>Y.F.</given-names></name><name><surname>Zhang</surname><given-names>W.G.</given-names></name><name><surname>Luo</surname><given-names>H.P.</given-names></name><etal/></person-group><article-title>Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma</article-title><source>BMC Cancer</source><year>2018</year><volume>18</volume><elocation-id>835</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-018-4744-4</pub-id><pub-id pub-id-type="pmid">30126375</pub-id></element-citation></ref><ref id="B92-cancers-12-00743"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haga</surname><given-names>N.</given-names></name><name><surname>Onagi</surname><given-names>A.</given-names></name><name><surname>Koguchi</surname><given-names>T.</given-names></name><name><surname>Hoshi</surname><given-names>S.</given-names></name><name><surname>Ogawa</surname><given-names>S.</given-names></name><name><surname>Akaihata</surname><given-names>H.</given-names></name><name><surname>Hata</surname><given-names>J.</given-names></name><name><surname>Hiraki</surname><given-names>H.</given-names></name><name><surname>Honda</surname><given-names>R.</given-names></name><name><surname>Tanji</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Perioperative Detection of Circulating Tumor Cells in Radical or Partial Nephrectomy for Renal Cell Carcinoma</article-title><source>Ann. Surg. Oncol.</source><year>2019</year><pub-id pub-id-type="doi">10.1245/s10434-019-08127-8</pub-id><?supplied-pmid 31832914?><pub-id pub-id-type="pmid">31832914</pub-id></element-citation></ref><ref id="B93-cancers-12-00743"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X.Q.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>L.W.</given-names></name></person-group><article-title>Laparoscopic surgery for early cervical squamous cell carcinoma and its effect on the micrometastasis of cancer cells</article-title><source>Medicine (Baltimore)</source><year>2018</year><volume>97</volume><fpage>e11921</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000011921</pub-id><?supplied-pmid 30142804?><pub-id pub-id-type="pmid">30142804</pub-id></element-citation></ref><ref id="B94-cancers-12-00743"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wind</surname><given-names>J.</given-names></name><name><surname>Tuynman</surname><given-names>J.B.</given-names></name><name><surname>Tibbe</surname><given-names>A.G.</given-names></name><name><surname>Swennenhuis</surname><given-names>J.F.</given-names></name><name><surname>Richel</surname><given-names>D.J.</given-names></name><name><surname>van Berge Henegouwen</surname><given-names>M.I.</given-names></name><name><surname>Bemelman</surname><given-names>W.A.</given-names></name></person-group><article-title>Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood</article-title><source>Eur. J. Surg. Oncol.</source><year>2009</year><volume>35</volume><fpage>942</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2008.12.003</pub-id><?supplied-pmid 19153024?><pub-id pub-id-type="pmid">19153024</pub-id></element-citation></ref><ref id="B95-cancers-12-00743"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Yan</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name></person-group><article-title>Less micrometastatic risk related to circulating tumor cells after endoscopic breast cancer surgery compared to open surgery</article-title><source>BMC Cancer</source><year>2019</year><volume>19</volume><elocation-id>1070</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-019-6158-3</pub-id><pub-id pub-id-type="pmid">31703643</pub-id></element-citation></ref><ref id="B96-cancers-12-00743"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juratli</surname><given-names>M.A.</given-names></name><name><surname>Sarimollaoglu</surname><given-names>M.</given-names></name><name><surname>Siegel</surname><given-names>E.R.</given-names></name><name><surname>Nedosekin</surname><given-names>D.A.</given-names></name><name><surname>Galanzha</surname><given-names>E.I.</given-names></name><name><surname>Suen</surname><given-names>J.Y.</given-names></name><name><surname>Zharov</surname><given-names>V.P.</given-names></name></person-group><article-title>Real-time monitoring of circulating tumor cell release during tumor manipulation using in vivo photoacoustic and fluorescent flow cytometry</article-title><source>Head Neck</source><year>2014</year><volume>36</volume><fpage>1207</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1002/hed.23439</pub-id><pub-id pub-id-type="pmid">23913663</pub-id></element-citation></ref><ref id="B97-cancers-12-00743"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juratli</surname><given-names>M.A.</given-names></name><name><surname>Siegel</surname><given-names>E.R.</given-names></name><name><surname>Nedosekin</surname><given-names>D.A.</given-names></name><name><surname>Sarimollaoglu</surname><given-names>M.</given-names></name><name><surname>Jamshidi-Parsian</surname><given-names>A.</given-names></name><name><surname>Cai</surname><given-names>C.</given-names></name><name><surname>Menyaev</surname><given-names>Y.A.</given-names></name><name><surname>Suen</surname><given-names>J.Y.</given-names></name><name><surname>Galanzha</surname><given-names>E.I.</given-names></name><name><surname>Zharov</surname><given-names>V.P.</given-names></name></person-group><article-title>In Vivo Long-Term Monitoring of Circulating Tumor Cells Fluctuation during Medical Interventions</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0137613</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0137613</pub-id><pub-id pub-id-type="pmid">26367280</pub-id></element-citation></ref><ref id="B98-cancers-12-00743"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyavanagoudar</surname><given-names>S.</given-names></name><name><surname>Kale</surname><given-names>A.</given-names></name><name><surname>Bhat</surname><given-names>K.</given-names></name><name><surname>Hallikerimath</surname><given-names>S.</given-names></name></person-group><article-title>Reverse transcriptase polymerase chain reaction study to evaluate dissemination of cancer cells into circulation after incision biopsy in oral squamous cell carcinoma</article-title><source>Indian J. Dent. Res.</source><year>2008</year><volume>19</volume><fpage>315</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.4103/0970-9290.44534</pub-id><pub-id pub-id-type="pmid">19075434</pub-id></element-citation></ref><ref id="B99-cancers-12-00743"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusukawa</surname><given-names>J.</given-names></name><name><surname>Suefuji</surname><given-names>Y.</given-names></name><name><surname>Ryu</surname><given-names>F.</given-names></name><name><surname>Noguchi</surname><given-names>R.</given-names></name><name><surname>Iwamoto</surname><given-names>O.</given-names></name><name><surname>Kameyama</surname><given-names>T.</given-names></name></person-group><article-title>Dissemination of cancer cells into circulation occurs by incisional biopsy of oral squamous cell carcinoma</article-title><source>J. Oral Pathol. Med.</source><year>2000</year><volume>29</volume><fpage>303</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0714.2000.290703.x</pub-id><pub-id pub-id-type="pmid">10947245</pub-id></element-citation></ref><ref id="B100-cancers-12-00743"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>E.G.</given-names></name><name><surname>Baxter</surname><given-names>G.</given-names></name></person-group><article-title>Tumour seeding following percutaneous needle biopsy: The real story!</article-title><source>Clin. Radiol.</source><year>2011</year><volume>66</volume><fpage>1007</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1016/j.crad.2011.05.012</pub-id><pub-id pub-id-type="pmid">21784421</pub-id></element-citation></ref><ref id="B101-cancers-12-00743"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathenge</surname><given-names>E.G.</given-names></name><name><surname>Dean</surname><given-names>C.A.</given-names></name><name><surname>Clements</surname><given-names>D.</given-names></name><name><surname>Vaghar-Kashani</surname><given-names>A.</given-names></name><name><surname>Photopoulos</surname><given-names>S.</given-names></name><name><surname>Coyle</surname><given-names>K.M.</given-names></name><name><surname>Giacomantonio</surname><given-names>M.</given-names></name><name><surname>Malueth</surname><given-names>B.</given-names></name><name><surname>Nunokawa</surname><given-names>A.</given-names></name><name><surname>Jordan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model</article-title><source>Neoplasia</source><year>2014</year><volume>16</volume><fpage>950</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2014.09.004</pub-id><pub-id pub-id-type="pmid">25425969</pub-id></element-citation></ref><ref id="B102-cancers-12-00743"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joosse</surname><given-names>S.A.</given-names></name><name><surname>Beyer</surname><given-names>B.</given-names></name><name><surname>Gasch</surname><given-names>C.</given-names></name><name><surname>Nastaly</surname><given-names>P.</given-names></name><name><surname>Kuske</surname><given-names>A.</given-names></name><name><surname>Isbarn</surname><given-names>H.</given-names></name><name><surname>Horst</surname><given-names>L.J.</given-names></name><name><surname>Hille</surname><given-names>C.</given-names></name><name><surname>Gorges</surname><given-names>T.M.</given-names></name><name><surname>Cayrefourcq</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer</article-title><source>Clin. Chem.</source><year>2019</year><pub-id pub-id-type="doi">10.1373/clinchem.2019.310912</pub-id><?supplied-pmid 31601564?><pub-id pub-id-type="pmid">31601564</pub-id></element-citation></ref><ref id="B103-cancers-12-00743"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Essen</surname><given-names>C.F.</given-names></name></person-group><article-title>Radiation enhancement of metastasis: A review</article-title><source>Clin. Exp. Metastasis</source><year>1991</year><volume>9</volume><fpage>77</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1007/BF01756381</pub-id><?supplied-pmid 2032423?><pub-id pub-id-type="pmid">2032423</pub-id></element-citation></ref><ref id="B104-cancers-12-00743"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>H.S.</given-names></name><name><surname>Murphy</surname><given-names>E.D.</given-names></name></person-group><article-title>The effect of local roentgen irradiation on the biological behavior of a transplantable mouse carcinoma; increased frequency of pulmonary metastasis</article-title><source>J. Natl. Cancer Inst.</source><year>1949</year><volume>9</volume><fpage>407</fpage><lpage>413</lpage><?supplied-pmid 18153815?><pub-id pub-id-type="pmid">18153815</pub-id></element-citation></ref><ref id="B105-cancers-12-00743"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheldon</surname><given-names>P.W.</given-names></name><name><surname>Fowler</surname><given-names>J.F.</given-names></name></person-group><article-title>The effect of low-dose pre-operative X-irradiation of implanted mouse mammary carcinomas on local recurrence and metastasis</article-title><source>Br. J. Cancer</source><year>1976</year><volume>34</volume><fpage>401</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1038/bjc.1976.183</pub-id><?supplied-pmid 974005?><pub-id pub-id-type="pmid">974005</pub-id></element-citation></ref><ref id="B106-cancers-12-00743"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camphausen</surname><given-names>K.</given-names></name><name><surname>Moses</surname><given-names>M.A.</given-names></name><name><surname>Beecken</surname><given-names>W.D.</given-names></name><name><surname>Khan</surname><given-names>M.K.</given-names></name><name><surname>Folkman</surname><given-names>J.</given-names></name><name><surname>O&#x02019;Reilly</surname><given-names>M.S.</given-names></name></person-group><article-title>Radiation therapy to a primary tumor accelerates metastatic growth in mice</article-title><source>Cancer Res.</source><year>2001</year><volume>61</volume><fpage>2207</fpage><lpage>2211</lpage><?supplied-pmid 11280788?><pub-id pub-id-type="pmid">11280788</pub-id></element-citation></ref><ref id="B107-cancers-12-00743"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koonce</surname><given-names>N.A.</given-names></name><name><surname>Juratli</surname><given-names>M.A.</given-names></name><name><surname>Cai</surname><given-names>C.</given-names></name><name><surname>Sarimollaoglu</surname><given-names>M.</given-names></name><name><surname>Menyaev</surname><given-names>Y.A.</given-names></name><name><surname>Dent</surname><given-names>J.</given-names></name><name><surname>Quick</surname><given-names>C.M.</given-names></name><name><surname>Dings</surname><given-names>R.P.M.</given-names></name><name><surname>Nedosekin</surname><given-names>D.</given-names></name><name><surname>Zharov</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2017</year><volume>492</volume><fpage>507</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.08.053</pub-id><pub-id pub-id-type="pmid">28822765</pub-id></element-citation></ref><ref id="B108-cancers-12-00743"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Casal</surname><given-names>R.</given-names></name><name><surname>Bhattacharya</surname><given-names>C.</given-names></name><name><surname>Ganesh</surname><given-names>N.</given-names></name><name><surname>Bailey</surname><given-names>L.</given-names></name><name><surname>Basse</surname><given-names>P.</given-names></name><name><surname>Gibson</surname><given-names>M.</given-names></name><name><surname>Epperly</surname><given-names>M.</given-names></name><name><surname>Levina</surname><given-names>V.</given-names></name></person-group><article-title>Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes</article-title><source>Mol. Cancer</source><year>2013</year><volume>12</volume><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-12-94</pub-id><pub-id pub-id-type="pmid">23947765</pub-id></element-citation></ref><ref id="B109-cancers-12-00743"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rofstad</surname><given-names>E.K.</given-names></name><name><surname>Mathiesen</surname><given-names>B.</given-names></name><name><surname>Galappathi</surname><given-names>K.</given-names></name></person-group><article-title>Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: Radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-2658</pub-id><pub-id pub-id-type="pmid">14729600</pub-id></element-citation></ref><ref id="B110-cancers-12-00743"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernier</surname><given-names>J.</given-names></name><name><surname>Hall</surname><given-names>E.J.</given-names></name><name><surname>Giaccia</surname><given-names>A.</given-names></name></person-group><article-title>Radiation oncology: A century of achievements</article-title><source>Nat. Rev. Cancer</source><year>2004</year><volume>4</volume><fpage>737</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1038/nrc1451</pub-id><pub-id pub-id-type="pmid">15343280</pub-id></element-citation></ref><ref id="B111-cancers-12-00743"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>D.</given-names></name><name><surname>Stigbrand</surname><given-names>T.</given-names></name></person-group><article-title>Radiation-induced cell death mechanisms</article-title><source>Tumour Biol.</source><year>2010</year><volume>31</volume><fpage>363</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1007/s13277-010-0042-8</pub-id><pub-id pub-id-type="pmid">20490962</pub-id></element-citation></ref><ref id="B112-cancers-12-00743"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewey</surname><given-names>W.C.</given-names></name><name><surname>Ling</surname><given-names>C.C.</given-names></name><name><surname>Meyn</surname><given-names>R.E.</given-names></name></person-group><article-title>Radiation-induced apoptosis: Relevance to radiotherapy</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>1995</year><volume>33</volume><fpage>781</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1016/0360-3016(95)00214-8</pub-id><pub-id pub-id-type="pmid">7591884</pub-id></element-citation></ref><ref id="B113-cancers-12-00743"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>S.</given-names></name><name><surname>Comincini</surname><given-names>S.</given-names></name></person-group><article-title>Autophagy and ionizing radiation in tumors: The &#x0201c;survive or not survive&#x0201d; dilemma</article-title><source>J. Cell. Physiol.</source><year>2013</year><volume>228</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/jcp.24118</pub-id><?supplied-pmid 22585676?><pub-id pub-id-type="pmid">22585676</pub-id></element-citation></ref><ref id="B114-cancers-12-00743"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>T.B.</given-names></name><name><surname>Kunz-Schughart</surname><given-names>L.A.</given-names></name><name><surname>Grosse-Gehling</surname><given-names>P.</given-names></name><name><surname>Baumann</surname><given-names>M.</given-names></name></person-group><article-title>Cancer stem cells as a predictive factor in radiotherapy</article-title><source>Semin. Radiat. Oncol.</source><year>2012</year><volume>22</volume><fpage>151</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.semradonc.2011.12.003</pub-id><?supplied-pmid 22385922?><pub-id pub-id-type="pmid">22385922</pub-id></element-citation></ref><ref id="B115-cancers-12-00743"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butof</surname><given-names>R.</given-names></name><name><surname>Dubrovska</surname><given-names>A.</given-names></name><name><surname>Baumann</surname><given-names>M.</given-names></name></person-group><article-title>Clinical perspectives of cancer stem cell research in radiation oncology</article-title><source>Radiother. Oncol.</source><year>2013</year><volume>108</volume><fpage>388</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2013.06.002</pub-id><pub-id pub-id-type="pmid">23830466</pub-id></element-citation></ref><ref id="B116-cancers-12-00743"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilalta</surname><given-names>M.</given-names></name><name><surname>Rafat</surname><given-names>M.</given-names></name><name><surname>Giaccia</surname><given-names>A.J.</given-names></name><name><surname>Graves</surname><given-names>E.E.</given-names></name></person-group><article-title>Recruitment of circulating breast cancer cells is stimulated by radiotherapy</article-title><source>Cell Rep.</source><year>2014</year><volume>8</volume><fpage>402</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.06.011</pub-id><pub-id pub-id-type="pmid">25017065</pub-id></element-citation></ref><ref id="B117-cancers-12-00743"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Early Breast Cancer Trialists&#x02019; Collaborative Group</collab><name><surname>Darby</surname><given-names>S.</given-names></name><name><surname>McGale</surname><given-names>P.</given-names></name><name><surname>Correa</surname><given-names>C.</given-names></name><name><surname>Taylor</surname><given-names>C.</given-names></name><name><surname>Arriagada</surname><given-names>R.</given-names></name><name><surname>Clarke</surname><given-names>M.</given-names></name><name><surname>Cutter</surname><given-names>D.</given-names></name><name><surname>Davies</surname><given-names>C.</given-names></name><name><surname>Ewertz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials</article-title><source>Lancet</source><year>2011</year><volume>378</volume><fpage>1707</fpage><lpage>1716</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)61629-2</pub-id><pub-id pub-id-type="pmid">22019144</pub-id></element-citation></ref><ref id="B118-cancers-12-00743"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>O.A.</given-names></name><name><surname>Anderson</surname><given-names>R.L.</given-names></name><name><surname>Russell</surname><given-names>P.A.</given-names></name><name><surname>Cox</surname><given-names>R.A.</given-names></name><name><surname>Ivashkevich</surname><given-names>A.</given-names></name><name><surname>Swierczak</surname><given-names>A.</given-names></name><name><surname>Doherty</surname><given-names>J.P.</given-names></name><name><surname>Jacobs</surname><given-names>D.H.</given-names></name><name><surname>Smith</surname><given-names>J.</given-names></name><name><surname>Siva</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mobilization of viable tumor cells into the circulation during radiation therapy</article-title><source>Int. J. Radiat. Oncol. Biol. Phys.</source><year>2014</year><volume>88</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.10.033</pub-id><pub-id pub-id-type="pmid">24315565</pub-id></element-citation></ref><ref id="B119-cancers-12-00743"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorsey</surname><given-names>J.F.</given-names></name><name><surname>Kao</surname><given-names>G.D.</given-names></name><name><surname>MacArthur</surname><given-names>K.M.</given-names></name><name><surname>Ju</surname><given-names>M.</given-names></name><name><surname>Steinmetz</surname><given-names>D.</given-names></name><name><surname>Wileyto</surname><given-names>E.P.</given-names></name><name><surname>Simone</surname><given-names>C.B.</given-names><suffix>2nd</suffix></name><name><surname>Hahn</surname><given-names>S.M.</given-names></name></person-group><article-title>Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results</article-title><source>Cancer</source><year>2015</year><volume>121</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1002/cncr.28975</pub-id><pub-id pub-id-type="pmid">25241991</pub-id></element-citation></ref><ref id="B120-cancers-12-00743"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>C.R.</given-names></name><name><surname>Seagle</surname><given-names>B.L.</given-names></name><name><surname>Friedl</surname><given-names>T.W.P.</given-names></name><name><surname>Rack</surname><given-names>B.</given-names></name><name><surname>Lato</surname><given-names>K.</given-names></name><name><surname>Fink</surname><given-names>V.</given-names></name><name><surname>Cristofanilli</surname><given-names>M.</given-names></name><name><surname>Donnelly</surname><given-names>E.D.</given-names></name><name><surname>Janni</surname><given-names>W.</given-names></name><name><surname>Shahabi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Association of Circulating Tumor Cell Status with Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer</article-title><source>JAMA Oncol.</source><year>2018</year><volume>4</volume><fpage>e180163</fpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2018.0163</pub-id><pub-id pub-id-type="pmid">29800954</pub-id></element-citation></ref><ref id="B121-cancers-12-00743"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Bao</surname><given-names>G.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Sha</surname><given-names>H.</given-names></name></person-group><article-title>Hematogenous dissemination of lung cancer cells during surgery: Quantitative detection by flow cytometry and prognostic significance</article-title><source>Lung Cancer</source><year>2002</year><volume>37</volume><fpage>293</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/S0169-5002(02)00102-2</pub-id><pub-id pub-id-type="pmid">12234699</pub-id></element-citation></ref><ref id="B122-cancers-12-00743"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paez-Ribes</surname><given-names>M.</given-names></name><name><surname>Allen</surname><given-names>E.</given-names></name><name><surname>Hudock</surname><given-names>J.</given-names></name><name><surname>Takeda</surname><given-names>T.</given-names></name><name><surname>Okuyama</surname><given-names>H.</given-names></name><name><surname>Vinals</surname><given-names>F.</given-names></name><name><surname>Inoue</surname><given-names>M.</given-names></name><name><surname>Bergers</surname><given-names>G.</given-names></name><name><surname>Hanahan</surname><given-names>D.</given-names></name><name><surname>Casanovas</surname><given-names>O.</given-names></name></person-group><article-title>Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis</article-title><source>Cancer Cell</source><year>2009</year><volume>15</volume><fpage>220</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.01.027</pub-id><?supplied-pmid 19249680?><pub-id pub-id-type="pmid">19249680</pub-id></element-citation></ref><ref id="B123-cancers-12-00743"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebos</surname><given-names>J.M.</given-names></name><name><surname>Lee</surname><given-names>C.R.</given-names></name><name><surname>Cruz-Munoz</surname><given-names>W.</given-names></name><name><surname>Bjarnason</surname><given-names>G.A.</given-names></name><name><surname>Christensen</surname><given-names>J.G.</given-names></name><name><surname>Kerbel</surname><given-names>R.S.</given-names></name></person-group><article-title>Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis</article-title><source>Cancer Cell</source><year>2009</year><volume>15</volume><fpage>232</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.01.021</pub-id><?supplied-pmid 19249681?><pub-id pub-id-type="pmid">19249681</pub-id></element-citation></ref><ref id="B124-cancers-12-00743"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name></person-group><article-title>Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer</article-title><source>Br. J. Cancer</source><year>2016</year><volume>114</volume><fpage>138</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/bjc.2015.417</pub-id><?supplied-pmid 26784122?><pub-id pub-id-type="pmid">26784122</pub-id></element-citation></ref><ref id="B125-cancers-12-00743"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>W.T.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>Y.F.</given-names></name><name><surname>Cui</surname><given-names>Y.H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name></person-group><article-title>Circulating tumor cell status monitors the treatment responses in breast cancer patients: A meta-analysis</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>43464</fpage><pub-id pub-id-type="doi">10.1038/srep43464</pub-id><pub-id pub-id-type="pmid">28337998</pub-id></element-citation></ref><ref id="B126-cancers-12-00743"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smerage</surname><given-names>J.B.</given-names></name><name><surname>Barlow</surname><given-names>W.E.</given-names></name><name><surname>Hortobagyi</surname><given-names>G.N.</given-names></name><name><surname>Winer</surname><given-names>E.P.</given-names></name><name><surname>Leyland-Jones</surname><given-names>B.</given-names></name><name><surname>Srkalovic</surname><given-names>G.</given-names></name><name><surname>Tejwani</surname><given-names>S.</given-names></name><name><surname>Schott</surname><given-names>A.F.</given-names></name><name><surname>O&#x02019;Rourke</surname><given-names>M.A.</given-names></name><name><surname>Lew</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>3483</fpage><lpage>3489</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.56.2561</pub-id><pub-id pub-id-type="pmid">24888818</pub-id></element-citation></ref><ref id="B127-cancers-12-00743"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebos</surname><given-names>J.M.</given-names></name><name><surname>Kerbel</surname><given-names>R.S.</given-names></name></person-group><article-title>Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2011</year><volume>8</volume><fpage>210</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2011.21</pub-id><pub-id pub-id-type="pmid">21364524</pub-id></element-citation></ref><ref id="B128-cancers-12-00743"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obenauf</surname><given-names>A.C.</given-names></name><name><surname>Zou</surname><given-names>Y.</given-names></name><name><surname>Ji</surname><given-names>A.L.</given-names></name><name><surname>Vanharanta</surname><given-names>S.</given-names></name><name><surname>Shu</surname><given-names>W.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Kong</surname><given-names>X.</given-names></name><name><surname>Bosenberg</surname><given-names>M.C.</given-names></name><name><surname>Wiesner</surname><given-names>T.</given-names></name><name><surname>Rosen</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Therapy-induced tumour secretomes promote resistance and tumour progression</article-title><source>Nature</source><year>2015</year><volume>520</volume><fpage>368</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1038/nature14336</pub-id><pub-id pub-id-type="pmid">25807485</pub-id></element-citation></ref><ref id="B129-cancers-12-00743"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>T.H.</given-names></name><name><surname>Lee</surname><given-names>S.O.</given-names></name><name><surname>Niu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>D.</given-names></name><name><surname>Liang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Yeh</surname><given-names>S.D.</given-names></name><name><surname>Fujimoto</surname><given-names>N.</given-names></name><name><surname>Yeh</surname><given-names>S.</given-names></name><name><surname>Chang</surname><given-names>C.</given-names></name></person-group><article-title>Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>19359</fpage><lpage>19369</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.477216</pub-id><pub-id pub-id-type="pmid">23687298</pub-id></element-citation></ref><ref id="B130-cancers-12-00743"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volk-Draper</surname><given-names>L.</given-names></name><name><surname>Hall</surname><given-names>K.</given-names></name><name><surname>Griggs</surname><given-names>C.</given-names></name><name><surname>Rajput</surname><given-names>S.</given-names></name><name><surname>Kohio</surname><given-names>P.</given-names></name><name><surname>DeNardo</surname><given-names>D.</given-names></name><name><surname>Ran</surname><given-names>S.</given-names></name></person-group><article-title>Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>5421</fpage><lpage>5434</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0067</pub-id><pub-id pub-id-type="pmid">25274031</pub-id></element-citation></ref><ref id="B131-cancers-12-00743"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pool</surname><given-names>S.E.</given-names></name><name><surname>Bison</surname><given-names>S.</given-names></name><name><surname>Koelewijn</surname><given-names>S.J.</given-names></name><name><surname>van der Graaf</surname><given-names>L.M.</given-names></name><name><surname>Melis</surname><given-names>M.</given-names></name><name><surname>Krenning</surname><given-names>E.P.</given-names></name><name><surname>de Jong</surname><given-names>M.</given-names></name></person-group><article-title>mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer</article-title><source>Cancer Res.</source><year>2013</year><volume>73</volume><fpage>12</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-2089</pub-id><pub-id pub-id-type="pmid">23149918</pub-id></element-citation></ref><ref id="B132-cancers-12-00743"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itescu</surname><given-names>S.</given-names></name><name><surname>Burke</surname><given-names>E.</given-names></name><name><surname>Lietz</surname><given-names>K.</given-names></name><name><surname>John</surname><given-names>R.</given-names></name><name><surname>Mancini</surname><given-names>D.</given-names></name><name><surname>Michler</surname><given-names>R.</given-names></name><name><surname>Rose</surname><given-names>E.</given-names></name><name><surname>Oz</surname><given-names>M.</given-names></name><name><surname>Edwards</surname><given-names>N.</given-names></name></person-group><article-title>Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients</article-title><source>Circulation</source><year>2002</year><volume>105</volume><fpage>1214</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1161/hc1002.105128</pub-id><pub-id pub-id-type="pmid">11889016</pub-id></element-citation></ref><ref id="B133-cancers-12-00743"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiavoni</surname><given-names>G.</given-names></name><name><surname>Mattei</surname><given-names>F.</given-names></name><name><surname>Di Pucchio</surname><given-names>T.</given-names></name><name><surname>Santini</surname><given-names>S.M.</given-names></name><name><surname>Bracci</surname><given-names>L.</given-names></name><name><surname>Belardelli</surname><given-names>F.</given-names></name><name><surname>Proietti</surname><given-names>E.</given-names></name></person-group><article-title>Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: Implications for strategies of chemoimmunotherapy of cancer</article-title><source>Blood</source><year>2000</year><volume>95</volume><fpage>2024</fpage><lpage>2030</lpage><pub-id pub-id-type="doi">10.1182/blood.V95.6.2024</pub-id><pub-id pub-id-type="pmid">10706870</pub-id></element-citation></ref><ref id="B134-cancers-12-00743"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Man</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name></person-group><article-title>Cyclophosphamide promotes pulmonary metastasis on mouse lung adenocarcinoma</article-title><source>Clin. Exp. Metastasis</source><year>2008</year><volume>25</volume><fpage>855</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1007/s10585-008-9201-3</pub-id><?supplied-pmid 18766303?><pub-id pub-id-type="pmid">18766303</pub-id></element-citation></ref><ref id="B135-cancers-12-00743"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname><given-names>K.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Hayashi</surname><given-names>K.</given-names></name><name><surname>Jiang</surname><given-names>P.</given-names></name><name><surname>Yamamoto</surname><given-names>N.</given-names></name><name><surname>Tsuchiya</surname><given-names>H.</given-names></name><name><surname>Tomita</surname><given-names>K.</given-names></name><name><surname>Moossa</surname><given-names>A.R.</given-names></name><name><surname>Bouvet</surname><given-names>M.</given-names></name><name><surname>Hoffman</surname><given-names>R.M.</given-names></name></person-group><article-title>Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: An opposite effect of chemotherapy</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>516</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-3063</pub-id><?supplied-pmid 18199547?><pub-id pub-id-type="pmid">18199547</pub-id></element-citation></ref><ref id="B136-cancers-12-00743"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.J.</given-names></name><name><surname>Muldoon</surname><given-names>L.L.</given-names></name><name><surname>Dickey</surname><given-names>D.T.</given-names></name><name><surname>Lewin</surname><given-names>S.J.</given-names></name><name><surname>Varallyay</surname><given-names>C.G.</given-names></name><name><surname>Neuwelt</surname><given-names>E.A.</given-names></name></person-group><article-title>Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models</article-title><source>Neoplasia</source><year>2009</year><volume>11</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1593/neo.81352</pub-id><?supplied-pmid 19177203?><pub-id pub-id-type="pmid">19177203</pub-id></element-citation></ref><ref id="B137-cancers-12-00743"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daenen</surname><given-names>L.G.</given-names></name><name><surname>Roodhart</surname><given-names>J.M.</given-names></name><name><surname>van Amersfoort</surname><given-names>M.</given-names></name><name><surname>Dehnad</surname><given-names>M.</given-names></name><name><surname>Roessingh</surname><given-names>W.</given-names></name><name><surname>Ulfman</surname><given-names>L.H.</given-names></name><name><surname>Derksen</surname><given-names>P.W.</given-names></name><name><surname>Voest</surname><given-names>E.E.</given-names></name></person-group><article-title>Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells</article-title><source>Cancer Res.</source><year>2011</year><volume>71</volume><fpage>6976</fpage><lpage>6985</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-0627</pub-id><?supplied-pmid 21975929?><pub-id pub-id-type="pmid">21975929</pub-id></element-citation></ref><ref id="B138-cancers-12-00743"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaigorodova</surname><given-names>E.V.</given-names></name><name><surname>Savelieva</surname><given-names>O.E.</given-names></name><name><surname>Tashireva</surname><given-names>L.A.</given-names></name><name><surname>Tarabanovskaya</surname><given-names>N.A.</given-names></name><name><surname>Simolina</surname><given-names>E.I.</given-names></name><name><surname>Denisov</surname><given-names>E.V.</given-names></name><name><surname>Slonimskaya</surname><given-names>E.M.</given-names></name><name><surname>Choynzonov</surname><given-names>E.L.</given-names></name><name><surname>Perelmuter</surname><given-names>V.M.</given-names></name></person-group><article-title>Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer</article-title><source>Molecules</source><year>2018</year><volume>23</volume><elocation-id>727</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23040727</pub-id></element-citation></ref><ref id="B139-cancers-12-00743"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadaki</surname><given-names>M.A.</given-names></name><name><surname>Stoupis</surname><given-names>G.</given-names></name><name><surname>Theodoropoulos</surname><given-names>P.A.</given-names></name><name><surname>Mavroudis</surname><given-names>D.</given-names></name><name><surname>Georgoulias</surname><given-names>V.</given-names></name><name><surname>Agelaki</surname><given-names>S.</given-names></name></person-group><article-title>Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer</article-title><source>Mol. Cancer Ther.</source><year>2019</year><volume>18</volume><fpage>437</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-0584</pub-id><pub-id pub-id-type="pmid">30401696</pub-id></element-citation></ref><ref id="B140-cancers-12-00743"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balzer</surname><given-names>E.M.</given-names></name><name><surname>Whipple</surname><given-names>R.A.</given-names></name><name><surname>Cho</surname><given-names>E.H.</given-names></name><name><surname>Matrone</surname><given-names>M.A.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>Antimitotic chemotherapeutics promote adhesive responses in detached and circulating tumor cells</article-title><source>Breast Cancer Res. Treat.</source><year>2010</year><volume>121</volume><fpage>65</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1007/s10549-009-0457-3</pub-id><pub-id pub-id-type="pmid">19593636</pub-id></element-citation></ref><ref id="B141-cancers-12-00743"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charpentier</surname><given-names>M.S.</given-names></name><name><surname>Whipple</surname><given-names>R.A.</given-names></name><name><surname>Vitolo</surname><given-names>M.I.</given-names></name><name><surname>Boggs</surname><given-names>A.E.</given-names></name><name><surname>Slovic</surname><given-names>J.</given-names></name><name><surname>Thompson</surname><given-names>K.N.</given-names></name><name><surname>Bhandary</surname><given-names>L.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>1250</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-1778</pub-id><pub-id pub-id-type="pmid">24371229</pub-id></element-citation></ref><ref id="B142-cancers-12-00743"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matrone</surname><given-names>M.A.</given-names></name><name><surname>Whipple</surname><given-names>R.A.</given-names></name><name><surname>Balzer</surname><given-names>E.M.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>Microtentacles tip the balance of cytoskeletal forces in circulating tumor cells</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>7737</fpage><lpage>7741</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1569</pub-id><?supplied-pmid 20924109?><pub-id pub-id-type="pmid">20924109</pub-id></element-citation></ref><ref id="B143-cancers-12-00743"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whipple</surname><given-names>R.A.</given-names></name><name><surname>Matrone</surname><given-names>M.A.</given-names></name><name><surname>Cho</surname><given-names>E.H.</given-names></name><name><surname>Balzer</surname><given-names>E.M.</given-names></name><name><surname>Vitolo</surname><given-names>M.I.</given-names></name><name><surname>Yoon</surname><given-names>J.R.</given-names></name><name><surname>Ioffe</surname><given-names>O.B.</given-names></name><name><surname>Tuttle</surname><given-names>K.C.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>8127</fpage><lpage>8137</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-4613</pub-id><?supplied-pmid 20924103?><pub-id pub-id-type="pmid">20924103</pub-id></element-citation></ref><ref id="B144-cancers-12-00743"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>B.D.</given-names></name><name><surname>Jones</surname><given-names>J.G.</given-names></name></person-group><article-title>Tumor microenvironment of metastasis (TMEM): A novel tissue-based assay for metastatic risk in breast cancer</article-title><source>Future Oncol.</source><year>2009</year><volume>5</volume><fpage>919</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.2217/fon.09.79</pub-id><?supplied-pmid 19792958?><pub-id pub-id-type="pmid">19792958</pub-id></element-citation></ref><ref id="B145-cancers-12-00743"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>B.D.</given-names></name><name><surname>Sica</surname><given-names>G.L.</given-names></name><name><surname>Liu</surname><given-names>Y.F.</given-names></name><name><surname>Rohan</surname><given-names>T.E.</given-names></name><name><surname>Gertler</surname><given-names>F.B.</given-names></name><name><surname>Condeelis</surname><given-names>J.S.</given-names></name><name><surname>Jones</surname><given-names>J.G.</given-names></name></person-group><article-title>Tumor microenvironment of metastasis in human breast carcinoma: A potential prognostic marker linked to hematogenous dissemination</article-title><source>Clin. Cancer Res.</source><year>2009</year><volume>15</volume><fpage>2433</fpage><lpage>2441</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2179</pub-id><pub-id pub-id-type="pmid">19318480</pub-id></element-citation></ref><ref id="B146-cancers-12-00743"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohan</surname><given-names>T.E.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>H.M.</given-names></name><name><surname>D&#x02019;Alfonso</surname><given-names>T.M.</given-names></name><name><surname>Ginter</surname><given-names>P.S.</given-names></name><name><surname>Oktay</surname><given-names>M.H.</given-names></name><name><surname>Robinson</surname><given-names>B.D.</given-names></name><name><surname>Ginsberg</surname><given-names>M.</given-names></name><name><surname>Gertler</surname><given-names>F.B.</given-names></name><name><surname>Glass</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer</article-title><source>J. Natl. Cancer Inst.</source><year>2014</year><volume>106</volume><pub-id pub-id-type="doi">10.1093/jnci/dju136</pub-id></element-citation></ref><ref id="B147-cancers-12-00743"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oktay</surname><given-names>M.H.</given-names></name><name><surname>Gertler</surname><given-names>F.B.</given-names></name><name><surname>Liu</surname><given-names>Y.F.</given-names></name><name><surname>Rohan</surname><given-names>T.E.</given-names></name><name><surname>Condeelis</surname><given-names>J.S.</given-names></name><name><surname>Jones</surname><given-names>J.G.</given-names></name></person-group><article-title>Correlated immunohistochemical and cytological assays for the prediction of hematogenous dissemination of breast cancer</article-title><source>J. Histochem. Cytochem.</source><year>2012</year><volume>60</volume><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1369/0022155411435153</pub-id><pub-id pub-id-type="pmid">22215635</pub-id></element-citation></ref><ref id="B148-cancers-12-00743"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastogi</surname><given-names>P.</given-names></name><name><surname>Anderson</surname><given-names>S.J.</given-names></name><name><surname>Bear</surname><given-names>H.D.</given-names></name><name><surname>Geyer</surname><given-names>C.E.</given-names></name><name><surname>Kahlenberg</surname><given-names>M.S.</given-names></name><name><surname>Robidoux</surname><given-names>A.</given-names></name><name><surname>Margolese</surname><given-names>R.G.</given-names></name><name><surname>Hoehn</surname><given-names>J.L.</given-names></name><name><surname>Vogel</surname><given-names>V.G.</given-names></name><name><surname>Dakhil</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27</article-title><source>J. Clin. Oncol.</source><year>2008</year><volume>26</volume><fpage>778</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.0235</pub-id><pub-id pub-id-type="pmid">18258986</pub-id></element-citation></ref><ref id="B149-cancers-12-00743"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianni</surname><given-names>L.</given-names></name><name><surname>Dafni</surname><given-names>U.</given-names></name><name><surname>Gelber</surname><given-names>R.D.</given-names></name><name><surname>Azambuja</surname><given-names>E.</given-names></name><name><surname>Muehlbauer</surname><given-names>S.</given-names></name><name><surname>Goldhirsch</surname><given-names>A.</given-names></name><name><surname>Untch</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>I.</given-names></name><name><surname>Baselga</surname><given-names>J.</given-names></name><name><surname>Jackisch</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial</article-title><source>Lancet Oncol.</source><year>2011</year><volume>12</volume><fpage>236</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(11)70033-X</pub-id><pub-id pub-id-type="pmid">21354370</pub-id></element-citation></ref><ref id="B150-cancers-12-00743"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harney</surname><given-names>A.S.</given-names></name><name><surname>Arwert</surname><given-names>E.N.</given-names></name><name><surname>Entenberg</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>P.</given-names></name><name><surname>Qian</surname><given-names>B.Z.</given-names></name><name><surname>Oktay</surname><given-names>M.H.</given-names></name><name><surname>Pollard</surname><given-names>J.W.</given-names></name><name><surname>Jones</surname><given-names>J.G.</given-names></name><name><surname>Condeelis</surname><given-names>J.S.</given-names></name></person-group><article-title>Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA</article-title><source>Cancer Discov.</source><year>2015</year><volume>5</volume><fpage>932</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0012</pub-id><pub-id pub-id-type="pmid">26269515</pub-id></element-citation></ref><ref id="B151-cancers-12-00743"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagiannis</surname><given-names>G.S.</given-names></name><name><surname>Goswami</surname><given-names>S.</given-names></name><name><surname>Jones</surname><given-names>J.G.</given-names></name><name><surname>Oktay</surname><given-names>M.H.</given-names></name><name><surname>Condeelis</surname><given-names>J.S.</given-names></name></person-group><article-title>Signatures of breast cancer metastasis at a glance</article-title><source>J. Cell Sci.</source><year>2016</year><volume>129</volume><fpage>1751</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1242/jcs.183129</pub-id><pub-id pub-id-type="pmid">27084578</pub-id></element-citation></ref><ref id="B152-cancers-12-00743"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagiannis</surname><given-names>G.S.</given-names></name><name><surname>Pastoriza</surname><given-names>J.M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Harney</surname><given-names>A.S.</given-names></name><name><surname>Entenberg</surname><given-names>D.</given-names></name><name><surname>Pignatelli</surname><given-names>J.</given-names></name><name><surname>Sharma</surname><given-names>V.P.</given-names></name><name><surname>Xue</surname><given-names>E.A.</given-names></name><name><surname>Cheng</surname><given-names>E.</given-names></name><name><surname>D&#x02019;Alfonso</surname><given-names>T.M.</given-names></name><etal/></person-group><article-title>Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism</article-title><source>Sci. Transl. Med.</source><year>2017</year><volume>9</volume><pub-id pub-id-type="doi">10.1126/scitranslmed.aan0026</pub-id><?supplied-pmid 28679654?><pub-id pub-id-type="pmid">28679654</pub-id></element-citation></ref><ref id="B153-cancers-12-00743"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y.S.</given-names></name><name><surname>Jalgaonkar</surname><given-names>S.P.</given-names></name><name><surname>Middleton</surname><given-names>J.D.</given-names></name><name><surname>Hai</surname><given-names>T.</given-names></name></person-group><article-title>Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>E7159</fpage><lpage>E7168</lpage><pub-id pub-id-type="doi">10.1073/pnas.1700455114</pub-id><?supplied-pmid 28784776?><pub-id pub-id-type="pmid">28784776</pub-id></element-citation></ref><ref id="B154-cancers-12-00743"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goss</surname><given-names>P.E.</given-names></name><name><surname>Chambers</surname><given-names>A.F.</given-names></name></person-group><article-title>Does tumour dormancy offer a therapeutic target?</article-title><source>Nat. Rev. Cancer</source><year>2010</year><volume>10</volume><fpage>871</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1038/nrc2933</pub-id><?supplied-pmid 21048784?><pub-id pub-id-type="pmid">21048784</pub-id></element-citation></ref><ref id="B155-cancers-12-00743"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>K.R.</given-names></name><name><surname>Hessler</surname><given-names>L.</given-names></name><name><surname>Bhandary</surname><given-names>L.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>Molecular Pathways: New Signaling Considerations When Targeting Cytoskeletal Balance to Reduce Tumor Growth</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>5209</fpage><lpage>5214</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0328</pub-id><?supplied-pmid 26463706?><pub-id pub-id-type="pmid">26463706</pub-id></element-citation></ref><ref id="B156-cancers-12-00743"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balzer</surname><given-names>E.M.</given-names></name><name><surname>Whipple</surname><given-names>R.A.</given-names></name><name><surname>Thompson</surname><given-names>K.</given-names></name><name><surname>Boggs</surname><given-names>A.E.</given-names></name><name><surname>Slovic</surname><given-names>J.</given-names></name><name><surname>Cho</surname><given-names>E.H.</given-names></name><name><surname>Matrone</surname><given-names>M.A.</given-names></name><name><surname>Yoneda</surname><given-names>T.</given-names></name><name><surname>Mueller</surname><given-names>S.C.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>c-Src differentially regulates the functions of microtentacles and invadopodia</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>6402</fpage><lpage>6408</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.360</pub-id><?supplied-pmid 20956943?><pub-id pub-id-type="pmid">20956943</pub-id></element-citation></ref><ref id="B157-cancers-12-00743"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boggs</surname><given-names>A.E.</given-names></name><name><surname>Vitolo</surname><given-names>M.I.</given-names></name><name><surname>Whipple</surname><given-names>R.A.</given-names></name><name><surname>Charpentier</surname><given-names>M.S.</given-names></name><name><surname>Goloubeva</surname><given-names>O.G.</given-names></name><name><surname>Ioffe</surname><given-names>O.B.</given-names></name><name><surname>Tuttle</surname><given-names>K.C.</given-names></name><name><surname>Slovic</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Mills</surname><given-names>G.B.</given-names></name><etal/></person-group><article-title>alpha-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration</article-title><source>Cancer Res.</source><year>2015</year><volume>75</volume><fpage>203</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-3563</pub-id><pub-id pub-id-type="pmid">25503560</pub-id></element-citation></ref><ref id="B158-cancers-12-00743"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitolo</surname><given-names>M.I.</given-names></name><name><surname>Boggs</surname><given-names>A.E.</given-names></name><name><surname>Whipple</surname><given-names>R.A.</given-names></name><name><surname>Yoon</surname><given-names>J.R.</given-names></name><name><surname>Thompson</surname><given-names>K.</given-names></name><name><surname>Matrone</surname><given-names>M.A.</given-names></name><name><surname>Cho</surname><given-names>E.H.</given-names></name><name><surname>Balzer</surname><given-names>E.M.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin</article-title><source>Oncogene</source><year>2013</year><volume>32</volume><fpage>2200</fpage><lpage>2210</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.234</pub-id><pub-id pub-id-type="pmid">22689060</pub-id></element-citation></ref><ref id="B159-cancers-12-00743"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whipple</surname><given-names>R.A.</given-names></name><name><surname>Balzer</surname><given-names>E.M.</given-names></name><name><surname>Cho</surname><given-names>E.H.</given-names></name><name><surname>Matrone</surname><given-names>M.A.</given-names></name><name><surname>Yoon</surname><given-names>J.R.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells</article-title><source>Cancer Res.</source><year>2008</year><volume>68</volume><fpage>5678</fpage><lpage>5688</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6589</pub-id><pub-id pub-id-type="pmid">18632620</pub-id></element-citation></ref><ref id="B160-cancers-12-00743"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whipple</surname><given-names>R.A.</given-names></name><name><surname>Cheung</surname><given-names>A.M.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>Detyrosinated microtubule protrusions in suspended mammary epithelial cells promote reattachment</article-title><source>Exp. Cell Res.</source><year>2007</year><volume>313</volume><fpage>1326</fpage><lpage>1336</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2007.02.001</pub-id><pub-id pub-id-type="pmid">17359970</pub-id></element-citation></ref><ref id="B161-cancers-12-00743"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>J.R.</given-names></name><name><surname>Whipple</surname><given-names>R.A.</given-names></name><name><surname>Balzer</surname><given-names>E.M.</given-names></name><name><surname>Cho</surname><given-names>E.H.</given-names></name><name><surname>Matrone</surname><given-names>M.A.</given-names></name><name><surname>Peckham</surname><given-names>M.</given-names></name><name><surname>Martin</surname><given-names>S.S.</given-names></name></person-group><article-title>Local anesthetics inhibit kinesin motility and microtentacle protrusions in human epithelial and breast tumor cells</article-title><source>Breast Cancer Res. Treat.</source><year>2011</year><volume>129</volume><fpage>691</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1007/s10549-010-1239-7</pub-id><pub-id pub-id-type="pmid">21069453</pub-id></element-citation></ref><ref id="B162-cancers-12-00743"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>S.P.</given-names></name><name><surname>Cabrera</surname><given-names>R.M.</given-names></name><name><surname>Segall</surname><given-names>J.E.</given-names></name></person-group><article-title>Tumor cell intravasation</article-title><source>Am. J. Physiol. Cell Physiol.</source><year>2016</year><volume>311</volume><fpage>C1</fpage><lpage>C14</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00238.2015</pub-id><?supplied-pmid 27076614?><pub-id pub-id-type="pmid">27076614</pub-id></element-citation></ref><ref id="B163-cancers-12-00743"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>G.P.</given-names></name><name><surname>Massague</surname><given-names>J.</given-names></name></person-group><article-title>Platelets and metastasis revisited: A novel fatty link</article-title><source>J. Clin. Investig.</source><year>2004</year><volume>114</volume><fpage>1691</fpage><lpage>1693</lpage><pub-id pub-id-type="doi">10.1172/JCI200423823</pub-id><?supplied-pmid 15599391?><pub-id pub-id-type="pmid">15599391</pub-id></element-citation></ref><ref id="B164-cancers-12-00743"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labelle</surname><given-names>M.</given-names></name><name><surname>Begum</surname><given-names>S.</given-names></name><name><surname>Hynes</surname><given-names>R.O.</given-names></name></person-group><article-title>Platelets guide the formation of early metastatic niches</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>E3053</fpage><lpage>E3061</lpage><pub-id pub-id-type="doi">10.1073/pnas.1411082111</pub-id><?supplied-pmid 25024172?><pub-id pub-id-type="pmid">25024172</pub-id></element-citation></ref><ref id="B165-cancers-12-00743"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uppal</surname><given-names>A.</given-names></name><name><surname>Wightman</surname><given-names>S.C.</given-names></name><name><surname>Ganai</surname><given-names>S.</given-names></name><name><surname>Weichselbaum</surname><given-names>R.R.</given-names></name><name><surname>An</surname><given-names>G.</given-names></name></person-group><article-title>Investigation of the essential role of platelet-tumor cell interactions in metastasis progression using an agent-based model</article-title><source>Theor. Biol. Med. Model.</source><year>2014</year><volume>11</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/1742-4682-11-17</pub-id><pub-id pub-id-type="pmid">24725600</pub-id></element-citation></ref><ref id="B166-cancers-12-00743"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gkountela</surname><given-names>S.</given-names></name><name><surname>Castro-Giner</surname><given-names>F.</given-names></name><name><surname>Szczerba</surname><given-names>B.M.</given-names></name><name><surname>Vetter</surname><given-names>M.</given-names></name><name><surname>Landin</surname><given-names>J.</given-names></name><name><surname>Scherrer</surname><given-names>R.</given-names></name><name><surname>Krol</surname><given-names>I.</given-names></name><name><surname>Scheidmann</surname><given-names>M.C.</given-names></name><name><surname>Beisel</surname><given-names>C.</given-names></name><name><surname>Stirnimann</surname><given-names>C.U.</given-names></name><etal/></person-group><article-title>Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>98</fpage><lpage>112.e114</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.11.046</pub-id><pub-id pub-id-type="pmid">30633912</pub-id></element-citation></ref><ref id="B167-cancers-12-00743"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zijlstra</surname><given-names>A.</given-names></name><name><surname>Von Lersner</surname><given-names>A.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Borrello</surname><given-names>L.</given-names></name><name><surname>Oudin</surname><given-names>M.</given-names></name><name><surname>Kang</surname><given-names>Y.</given-names></name><name><surname>Sahai</surname><given-names>E.</given-names></name><name><surname>Fingleton</surname><given-names>B.</given-names></name><name><surname>Stein</surname><given-names>U.</given-names></name><name><surname>Cox</surname><given-names>T.R.</given-names></name><etal/></person-group><article-title>The importance of developing therapies targeting the biological spectrum of metastatic disease</article-title><source>Clin. Exp. Metastasis</source><year>2019</year><volume>36</volume><fpage>305</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1007/s10585-019-09972-3</pub-id><pub-id pub-id-type="pmid">31102066</pub-id></element-citation></ref><ref id="B168-cancers-12-00743"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>R.L.</given-names></name><name><surname>Balasas</surname><given-names>T.</given-names></name><name><surname>Callaghan</surname><given-names>J.</given-names></name><name><surname>Coombes</surname><given-names>R.C.</given-names></name><name><surname>Evans</surname><given-names>J.</given-names></name><name><surname>Hall</surname><given-names>J.A.</given-names></name><name><surname>Kinrade</surname><given-names>S.</given-names></name><name><surname>Jones</surname><given-names>D.</given-names></name><name><surname>Jones</surname><given-names>P.S.</given-names></name><name><surname>Jones</surname><given-names>R.</given-names></name><etal/></person-group><article-title>A framework for the development of effective anti-metastatic agents</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2019</year><volume>16</volume><fpage>185</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1038/s41571-018-0134-8</pub-id><pub-id pub-id-type="pmid">30514977</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="cancers-12-00743-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Tumor cell dissemination. Once tumor cells have entered the bloodstream, they may die due to apoptosis, sheer stress, or fragmentation when being pushed through tiny capillaries. In the minor cases that circulating tumor cells (CTCs) are viable and survive, they may be able to continue the metastatic process. At which point, they would need to attach to the endothelial cell wall, extravasate, and invade into the surrounding tissue where they may lay dormant for years before becoming an overt micrometastasis. Individual CTCs do not remain in the bloodstream long (~10&#x02013;15min at the most) before they reach the closes capillary bed.</p></caption><graphic xlink:href="cancers-12-00743-g001"/></fig><fig id="cancers-12-00743-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>All current treatment modalities have the potential to promote CTCs. Early studies have shown that pressure such as that from mammograms (<bold>a</bold>) and tumor palpations (<bold>b</bold>) may promote tumor cell release. Surgical procedures (<bold>c</bold>) including biopsies and complete tumor resections can promote CTCs. Other possible primary tumor curative treatments such as radiotherapy (<bold>d</bold>) and chemotherapy (<bold>e</bold>) may inadvertently increase CTCs. Figure adapted from nationalbreastcancer.org [<xref rid="B85-cancers-12-00743" ref-type="bibr">85</xref>].</p></caption><graphic xlink:href="cancers-12-00743-g002"/></fig></floats-group></article>